

Efficacy of atenolol and captopril in reducing risk of major complications in type 2 diabetes: UKPDS 39

BMJ: British Medical Journal

317, 713-720

DOI: [10.1136/bmj.317.7160.713](https://doi.org/10.1136/bmj.317.7160.713)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treatment of Diabetic Nephropathy in its Early Stages. , 1997, 13, 51-61.		17
3	The UK Prospective Diabetes study. Lancet, The, 1998, 352, 1934.	13.7	71
4	Some answers, more controversy, from UKPDS. Lancet, The, 1998, 352, 832-833.	13.7	167
5	Î-blockers were not as efficacious as diuretics when used as first-line therapy in elderly patients with uncomplicated hypertension. Evidence-based Cardiovascular Medicine, 1998, 2, 102.	0.0	0
6	Le diab??te de type 2 vu par l'??pid??miologiste. Disease Management and Health Outcomes, 1998, 4, 1-12.	0.4	2
7	Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ: British Medical Journal, 1998, 317, 703-713.	2.3	5,635
8	Diabetes: a time for excitement--and concern. BMJ: British Medical Journal, 1998, 317, 691-692.	2.3	19
9	Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. BMJ: British Medical Journal, 1998, 317, 693-694.	2.3	72
10	United Kingdom Prospective Diabetes Study: the end of the beginning?. Medical Journal of Australia, 1998, 169, 511-512.	1.7	0
11	Update in General Internal Medicine. Annals of Internal Medicine, 1999, 131, 199.	3.9	6
12	Blood pressure control in type 2 diabetes--what does the United Kingdom prospective diabetes study (UKPDS) tell us?. Nephrology Dialysis Transplantation, 1999, 14, 2562-2564.	0.7	12
13	Management of retinopathy in type 2 diabetes. Eye, 1999, 13, 131-132.	2.1	1
14	Calcium-Channel Blockade and Hypertension. New England Journal of Medicine, 1999, 341, 372-373.	27.0	3
15	Benefits of Strict Glucose and Blood Pressure Control in Type 2 Diabetes. Circulation, 1999, 99, 461-462.	1.6	59
16	Hypertension and diabetic retinopathy--what's the story?. British Journal of Ophthalmology, 1999, 83, 1083-1087.	3.9	53
17	Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus. Diabetic Medicine, 1999, 16, 358-372.	2.3	23
18	Diabetic Nephropathy. Diabetes Technology and Therapeutics, 1999, 1, 489-496.	4.4	7
19	Management of essential hypertension. Expert Opinion on Pharmacotherapy, 1999, 1, 71-80.	1.8	3

#	ARTICLE	IF	CITATIONS
21	The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 643-648.	2.4	436
22	UKPDS and beyond: into the next millennium. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 13-22.	4.4	17
23	Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 67-74.	4.4	36
24	Dyslipidaemia and cardiovascular risk in diabetes. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 189-198.	4.4	27
25	Clinical management of diabetic nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 307-315.	4.4	5
26	The natural history of diabetes-related complications: the UKPDS experience. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 7-13.	4.4	29
27	A five-year evaluation of intervention in diabetes care in Trinidad and Tobago. <i>Diabetic Medicine</i> , 1999, 16, 939-945.	2.3	24
28	Original Articles: 4. <i>Diabetic Medicine</i> , 1999, 16, 779-792.	2.3	0
29	An ace in the hole?. <i>Diabetic Medicine</i> , 1999, 16, 887-888.	2.3	2
30	Small is beautiful - but too cheap. <i>Diabetic Medicine</i> , 1999, 16, 445-445.	2.3	0
32	Controversies surrounding the treatment of the hypertensive patient with diabetes. <i>Current Hypertension Reports</i> , 1999, 1, 512-520.	3.5	9
33	Carcinogenicity of cardiovascular drugs. <i>Current Hypertension Reports</i> , 1999, 1, 212-218.	3.5	17
34	Recent outcome trials of newer antihypertensives. <i>Current Hypertension Reports</i> , 1999, 1, 238-240.	3.5	0
35	Recent clinical trials: A critical appraisal. <i>Current Hypertension Reports</i> , 1999, 1, 333-336.	3.5	4
36	The world health organization's International society of hypertension blood pressure lowering treatment trials' collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. <i>Current Hypertension Reports</i> , 1999, 1, 346-356.	3.5	19
37	Issues of clinical trial design and data interpretations in hypertension. <i>Current Hypertension Reports</i> , 1999, 1, 357-362.	3.5	0
38	Optimal blood pressure on antihypertensive medication. <i>Current Hypertension Reports</i> , 1999, 1, 381-386.	3.5	1
39	Importance of blood pressure reduction for prevention of progression of renal disease. <i>Current Hypertension Reports</i> , 1999, 1, 423-430.	3.5	1

#	ARTICLE	IF	CITATIONS
40	Do pharmacologic differences among antihypertensive agents point to clinical benefits?. American Journal of Cardiology, 1999, 84, 22-27.	1.6	1
41	The diabetic patient as paradigm for selective antihypertensive therapy. Clinical Cornerstone, 1999, 2, 1-12.	0.7	10
42	United Kingdom Prospective Diabetes Study (UKPDS): what now or so what?. Diabetes/Metabolism Research and Reviews, 1999, 15, 65-71.	4.0	35
43	THE TREATMENT OF HYPERTENSION AND DYSLIPIDEMIA IN DIABETES MELLITUS. Primary Care - Clinics in Office Practice, 1999, 26, 951-964.	1.6	5
44	Treatment of Diabetic Retinopathy. New England Journal of Medicine, 1999, 341, 667-678.	27.0	160
45	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Clinical and Experimental Hypertension, 1999, 21, 1009-1060.	1.3	471
46	An Overview of 37 Randomised Trials of Blood Pressure Lowering Agents Among 270,000 Individuals. Clinical and Experimental Hypertension, 1999, 21, 517-529.	1.3	14
47	Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors. Clinical and Experimental Hypertension, 1999, 21, 835-845.	1.3	19
48	Drug Treatment for Hypertensive Patients in Special Situations: Diabetes and Hypertension. Clinical and Experimental Hypertension, 1999, 21, 895-906.	1.3	22
49	Cost-Effectiveness Analysis in the Treatment of Hypertension: A Medical View. Clinical and Experimental Hypertension, 1999, 21, 999-1008.	1.3	8
50	CAPPP trial. Lancet, The, 1999, 353, 1793-1794.	13.7	5
51	Which drug for treatment of hypertension?. Lancet, The, 1999, 353, 604-605.	13.7	31
52	Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet, The, 1999, 353, 611-616.	13.7	1,938
53	Association between antihypertensive drug use and hypoglycemia: A case-control study of diabetic users of insulin or sulfonylureas. Clinical Therapeutics, 1999, 21, 1387-1400.	2.5	53
54	PREVENTION AND TREATMENT OF MICROVASCULAR AND NEUROPATHIC COMPLICATIONS OF DIABETES. Primary Care - Clinics in Office Practice, 1999, 26, 791-807.	1.6	5
56	Should All Pima Indians With Type 2 Diabetes Mellitus Be Prescribed Routine Angiotensin-Converting Enzyme Inhibition Therapy to Prevent Renal Failure?. Mayo Clinic Proceedings, 1999, 74, 559-564.	3.0	6
57	HYPERTENSION IN THE ELDERLY. Cardiology Clinics, 1999, 17, 79-92.	2.2	13
58	Renal Protection and Antihypertensive Drugs. Drugs, 1999, 57, 665-693.	10.9	46

#	ARTICLE	IF	CITATIONS
59	Calcium-Antagonist Drugs. New England Journal of Medicine, 1999, 341, 1447-1457.	27.0	393
60	ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina This document was approved by the American College of Cardiology Board of Trustees in March 1999, the American Heart Association Science Advisory and Coordinating Committee in March 1999, and the American College of Physicians-American Society of Internal Medicine Board of Regents in February 1999. When citing this document, please use the following citation format: Gibbons RJ, Chatterjee K, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Re-evaluate the 1999 Guidelines for the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 1999;34:982-1046. PMID: 10428417	2.8	608
61	Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients The analyses upon which this publication is based were performed under Contract No. 500-96-P549, entitled "Utilization and Quality Control Peer Review Organization for the State of Connecticut," sponsored by the Health Care Financing Administration, Department of Health and Human Services. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human. Journal of the American College of Cardiology, 1999, 34, 1388-139	2.8	91
62	Drug Therapy for Type 2 Diabetes. Journal of Pharmacy Practice, 1999, 12, 84-97.	1.0	0
63	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Journal of Hypertension, 1999, 17, 151-183.	0.5	1,232
64	Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial. Journal of Hypertension, 1999, 17, 1917-1923.	0.5	14
65	Effects of intensified antihypertensive treatment in diabetic nephropathy. Journal of Hypertension, 1999, 17, 1497-1503.	0.5	38
66	Diabetes in the Elderly Population. Advances in Chronic Kidney Disease, 2000, 7, 32-51.	2.1	14
67	Recent advances: Nephrology. BMJ: British Medical Journal, 2000, 320, 98-101.	2.3	16
68	Beta Blockers in Treatment of Heart Failure and Hypertension in Diabetes: Ugly Misconceptions Slain by Beautiful Clinical Data. The American Journal of Geriatric Cardiology, 2000, 9, 290-291.	0.6	0
69	That Was the Year That Was: An Evidence-Based Clinical Geriatrics Update 1998-1999. Journal of the American Geriatrics Society, 2000, 48, 1717-1725.	2.6	1
70	European Society of Hypertension Scientific Newsletter, Update on Hypertension Management. Journal of Hypertension, 2000, 18, 1345-1346.	0.5	5
71	Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?. Current Opinion in Nephrology and Hypertension, 2000, 9, 173-179.	2.0	6
72	Large multicentre hypertension trials. Current Opinion in Nephrology and Hypertension, 2000, 9, 285-292.	2.0	0
73	Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients. Journal of Hypertension, 2000, 18, 1671-1675.	0.5	172
74	Managing blood pressure in type 2 diabetes mellitus. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 49-53.	0.2	3
75	Angiotensin converting enzyme (ACE) activity levels in insulin-independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy. , 2000, 18, 23-28.		25
76	The HOPE Study: practical implications for people with diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 191-194.	0.2	9

#	ARTICLE	IF	CITATIONS
77	Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. <i>Kidney International</i> , 2000, 57, 590-600.	5.2	158
78	Experimental diabetic nephropathy: Is it relevant to the human disease. <i>Nephrology</i> , 2000, 5, 177-185.	1.6	4
79	The impact of antihypertensive therapy in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, S37-S41.	4.4	1
80	Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 3-14.	4.4	25
81	Direct medical costs for patients with type 2 diabetes in Sweden. <i>Journal of Internal Medicine</i> , 2000, 248, 387-396.	6.0	123
82	Diabetes mellitus and coronary heart disease –from prevention to intervention: Part I. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 351-359.	0.5	8
83	Fasting plasma glucose in non-diabetic elderly women predicts increased all-cause mortality and coronary heart disease risk. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 41-47.	0.5	31
84	Clinical trials and clinical practice –bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 483-491.	0.5	3
85	The prognosis for Type 2 diabetic patients with heart disease. <i>Journal of Diabetes and Its Complications</i> , 2000, 14, 301-306.	2.3	12
86	Doxazosin arm of the ALLHAT study discontinued: How equal are antihypertensive drugs?. <i>Current Hypertension Reports</i> , 2000, 2, 241-242.	3.5	4
87	Joint national committee VI: Individualized versus indiscriminate therapy for hypertension. <i>Current Hypertension Reports</i> , 2000, 2, 243-246.	3.5	3
88	Effects of antihypertensive therapy on hypertensive vascular disease. <i>Current Hypertension Reports</i> , 2000, 2, 280-288.	3.5	34
89	Treatment of hypertension in diabetes mellitus. <i>Current Hypertension Reports</i> , 2000, 2, 335-342.	3.5	8
90	Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents. <i>Current Hypertension Reports</i> , 2000, 2, 525-529.	3.5	5
91	Antihypertensive Therapy and the Risk of Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2000, 342, 969-970.	27.0	125
92	Importance of Systolic Blood Pressure in Older Americans. <i>Hypertension</i> , 2000, 35, 1021-1024.	2.7	363
93	Hypertension in the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2000, 9, 130-137.	0.6	4
94	Anaesthetic management of patients with diabetes mellitus. <i>British Journal of Anaesthesia</i> , 2000, 85, 80-90.	3.4	91

#	ARTICLE	IF	CITATIONS
95	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. <i>BMJ: British Medical Journal</i> , 2000, 321, 412-419.	2.3	1,737
96	Preventing cardiovascular disease in hypertensive patients with type 2 diabetes. <i>Journal of Hypertension</i> , 2000, 18, 1553-1556.	0.5	1
97	Evidence-based therapy for type 2 diabetes. <i>Postgraduate Medicine</i> , 2000, 107, 27-47.	2.0	6
98	Effect of Ramipril on Cardiovascular Events in High-Risk Patients. <i>New England Journal of Medicine</i> , 2000, 343, 64-66.	27.0	29
99	Managing cardiovascular risk in patients with diabetes. <i>British Heart Journal</i> , 2000, 84, 23i-25.	2.1	0
100	Resting Metabolic Rate and Substrate Use in Obesity Hypertension. <i>Hypertension</i> , 2000, 36, 26-32.	2.7	66
101	Complications of diabetes: renal disease and promotion of self-management. <i>Quality in Health Care: QHC</i> , 2000, 9, 257-263.	1.2	5
102	The losartan renal protection study – rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000, 1, 328-335.	1.7	118
103	Cardiac, renal and vascular complications in the diabetic patient. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000, 1, 21-24.	1.7	0
104	Pathophysiology and Pharmacological Treatment of Insulin Resistance*. <i>Endocrine Reviews</i> , 2000, 21, 585-618.	20.1	263
105	Management of patients with hypertension and diabetes mellitus: advances in the evidence for intensive treatment. <i>American Journal of Medicine</i> , 2000, 108, 238-245.	1.5	31
106	The HOPE study and diabetes. <i>Lancet, The</i> , 2000, 355, 1183-1184.	13.7	19
107	HOPE and extension of the indications for ACE inhibitors?. <i>Lancet, The</i> , 2000, 355, 246-247.	13.7	18
108	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. <i>Lancet, The</i> , 2000, 355, 253-259.	13.7	3,134
109	Life-expectancy projection by modelling and computer simulation (UKPDS 46). <i>Diabetes Research and Clinical Practice</i> , 2000, 50, S5-S13.	2.8	22
110	Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. <i>Diabetes Research and Clinical Practice</i> , 2000, 47, 97-104.	2.8	18
111	The role of platelets in diabetes-related vascular complications. <i>Diabetes Research and Clinical Practice</i> , 2000, 50, 1-16.	2.8	111
112	Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study. <i>American Journal of Hypertension</i> , 2000, 13, 899-906.	2.0	54

#	ARTICLE	IF	CITATIONS
113	Treating high-risk diabetic hypertensive patients with comorbid conditions. <i>American Journal of Kidney Diseases</i> , 2000, 36, S10-S17.	1.9	17
114	Effect of enalapril on the incidence of retinopathy in normotensive patients with type 2 diabetes. <i>European Journal of Internal Medicine</i> , 2000, 11, 48-50.	2.2	6
115	Oxidative stress: Introduction. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 1-2.	3.4	1
116	The HOPE study and diabetes. <i>Lancet, The</i> , 2000, 355, 1181.	13.7	5
117	Randomised trial of effects of calcium antagonists compared with diuretics and β -blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. <i>Lancet, The</i> , 2000, 356, 359-365.	13.7	876
118	Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. <i>Lancet, The</i> , 2000, 356, 1955-1964.	13.7	1,559
119	Beneficial and Detrimental Effects of Intensive Glycaemic Control, with Emphasis on Type 2 Diabetes Mellitus. <i>Drugs and Aging</i> , 2000, 17, 463-476.	2.7	12
120	Implications of the UK Prospective Diabetes Study. <i>Drugs and Aging</i> , 2000, 16, 159-164.	2.7	18
121	Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2601-2617.	4.1	7
123	DANGEROUS AND COMMON DRUG INTERACTIONS IN PATIENTS WITH DIABETES MELLITUS. <i>Endocrinology and Metabolism Clinics of North America</i> , 2000, 29, 789-801.	3.2	31
124	MANAGEMENT OF ELDERLY DIABETIC PATIENTS IN THE SUBACUTE CARE SETTING. <i>Clinics in Geriatric Medicine</i> , 2000, 16, 833-852.	2.6	3
127	Pharmacotherapy of Type 2 Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2000, 34, 878-895.	1.9	24
128	La hipertensi3n arterial en la diabetes mellitus tipo 2. <i>Hipertension Y Riesgo Vascular</i> , 2000, 17, 272-283.	0.6	2
129	Irbesartan. <i>Drugs</i> , 2000, 59, 1187-1206.	10.9	39
130	Management of Type 2 Diabetes Mellitus and Cardiovascular Risk. <i>Drugs</i> , 2000, 60, 975-983.	10.9	41
131	CARDIOMYOPATHY AND HEART FAILURE IN DIABETES. <i>Endocrinology and Metabolism Clinics of North America</i> , 2001, 30, 1031-1046.	3.2	19
132	Drug-Induced Lipid Changes. <i>Drug Safety</i> , 2001, 24, 443-456.	3.2	100
133	??-Blockers in the Management of Hypertension in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2001, 61, 429-435.	10.9	7

#	ARTICLE	IF	CITATIONS
134	Hypertension in Diabetes Mellitus. <i>Drugs</i> , 2001, 61, 1531-1533.	10.9	0
135	HYPERTENSION. <i>Obstetrics and Gynecology Clinics of North America</i> , 2001, 28, 321-332.	1.9	0
136	MANAGEMENT OF TYPE 2 DIABETES. <i>Obstetrics and Gynecology Clinics of North America</i> , 2001, 28, 401-420.	1.9	1
138	Management of Diabetes Mellitus. <i>Disease Management and Health Outcomes</i> , 2001, 9, 711-730.	0.4	2
139	Diabetes, Hypertension, and Cardiovascular Disease. <i>Hypertension</i> , 2001, 37, 1053-1059.	2.7	1,076
140	Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2001, 345, 861-869.	27.0	6,609
141	Management of High-Risk Hypertensive Patients with Diabetes: Potential Role of Angiotensin II Receptor Antagonists. <i>Journal of Clinical Hypertension</i> , 2001, 3, 225-235.	2.0	3
142	The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. <i>American Journal of Medicine</i> , 2001, 111, 633-642.	1.5	159
143	Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?. <i>American Heart Journal</i> , 2001, 142, 857-863.	2.7	43
144	Systemic considerations in the management of diabetic retinopathy. <i>American Journal of Ophthalmology</i> , 2001, 132, 760-776.	3.3	159
145	Diabetes mellitus—a special medical challenge from a Chinese perspective. <i>Diabetes Research and Clinical Practice</i> , 2001, 54, 19-27.	2.8	33
146	An initial assessment of the feasibility and effectiveness of implementing diabetes shared care system in Taiwan—some experiences from I-Lan County. <i>Diabetes Research and Clinical Practice</i> , 2001, 54, 67-73.	2.8	34
147	Angiotensin-converting enzyme inhibitors. <i>Advances in Protein Chemistry</i> , 2001, 56, 13-75.	4.4	48
148	Adjusting for multiple testing—when and how?. <i>Journal of Clinical Epidemiology</i> , 2001, 54, 343-349.	5.0	2,133
149	Diabetes mellitus and diabetes-associated vascular disease. <i>Trends in Endocrinology and Metabolism</i> , 2001, 12, 225-230.	7.1	88
150	Diabetes mellitus: a major challenge in transplantation. <i>Transplantation Proceedings</i> , 2001, 33, S3-S7.	0.6	10
151	Strategies for risk reduction and management of posttransplant diabetes mellitus. <i>Transplantation Proceedings</i> , 2001, 33, S27-S31.	0.6	16
152	UPDATE IN PHARMACOLOGIC TREATMENT OF HYPERTENSION. <i>Cardiology Clinics</i> , 2001, 19, 279-294.	2.2	13

#	ARTICLE	IF	CITATIONS
154	Step Care Therapy for Hypertension in Diabetic Patients. Mayo Clinic Proceedings, 2001, 76, 1266-1274.	3.0	9
155	Complicaciones de la diabetes mellitus. Diagnóstico y tratamiento. Semergen, 2001, 27, 132-145.	0.5	6
156	MICROVASCULAR COMPLICATIONS. Endocrinology and Metabolism Clinics of North America, 2001, 30, 833-856.	3.2	51
157	Tratamiento de la insuficiencia cardíaca. Medidas preventivas. Factores de riesgo asociados. Medicine, 2001, 8, 1994-2000.	0.0	0
158	The current status of antihypertensive treatments: into the new millennium. Expert Opinion on Pharmacotherapy, 2001, 2, 731-737.	1.8	2
159	Management of type 2 diabetes: finding a sensible pathway through the maze of available agents. Drugs and Therapy Perspectives, 2001, 17, 4-8.	0.6	1
160	What is the Optimal Blood Pressure in Patients with Diabetes Mellitus?. American Journal of Cardiovascular Drugs, 2001, 1, 173-177.	2.2	3
161	Treatment of Obesity Hypertension and Diabetes Syndrome. Hypertension, 2001, 38, 705-708.	2.7	102
162	SYMPATHETIC NERVOUS SYSTEM, DIABETES, AND HYPERTENSION. Clinical and Experimental Hypertension, 2001, 23, 45-55.	1.3	134
163	Racial and Ethnic Differences in Health Care Access and Health Outcomes for Adults With Type 2 Diabetes. Diabetes Care, 2001, 24, 454-459.	8.6	346
164	Pharmacotherapy of hypertension in patients with diabetes mellitus. Expert Opinion on Pharmacotherapy, 2001, 2, 1805-1816.	1.8	4
165	Guidelines for the Management of Hypertension for General Practitioners.. Hypertension Research, 2001, 24, 613-634.	2.7	116
166	Evidence based management of hypertension: What are the elements of good treatment for hypertension?. BMJ: British Medical Journal, 2001, 322, 1107-1109.	2.3	22
167	Should Angiotensin-Converting Enzyme Inhibitors Be Added To The Water Supply Of Patients With Diabetes?. Endocrine Practice, 2001, 7, 59-63.	2.1	2
168	Containing the costs of managing hypertension. Medical Journal of Australia, 2001, 174, 556-557.	1.7	1
169	Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy?. Current Opinion in Nephrology and Hypertension, 2001, 10, 617-624.	2.0	37
170	Evolving strategies for renoprotection: diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2001, 10, 515-522.	2.0	76
171	Medication Management of Hypertension. Topics in Geriatric Rehabilitation, 2001, 17, 61-82.	0.4	2

#	ARTICLE	IF	CITATIONS
172	Treatment of Hypertension in Patients with Diabetes: Lessons from Recent Trials. <i>Cardiology in Review</i> , 2001, 9, 36-44.	1.4	9
173	Hypertension trials: 1990 to 2000. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 501-505.	2.0	12
174	Cardiovascular disease in diabetes: prevention and intervention. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2001, 8, 101-110.	0.6	3
175	The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 597-601.	2.0	21
176	EVIDENCE-BASED TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE 2 DIABETES. <i>Acta Clinica Belgica</i> , 2001, 56, 96-102.	1.2	0
177	Small Artery Remodeling in Hypertension: Can It Be Corrected?. <i>American Journal of the Medical Sciences</i> , 2001, 322, 7-11.	1.1	28
178	Impaired Renal Autoregulation: Implications for the Genesis of Hypertension and Hypertension-Induced Renal Injury. <i>American Journal of the Medical Sciences</i> , 2001, 321, 388-400.	1.1	51
179	Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. , 2001, 11, 474-490.		7
180	Lercanidipine. <i>Heart Disease (Hagerstown, Md)</i> , 2001, 3, 398-407.	1.3	34
181	Vascular complications in diabetes and their prevention. <i>Vascular Medicine</i> , 2001, 6, 249-255.	1.5	34
182	Choice of drug treatment for obesity-related hypertension: where is the evidence?. <i>Journal of Hypertension</i> , 2001, 19, 667-674.	0.5	78
183	Population-based estimates of mortality associated with diabetes: use of a death certificate check box in North Dakota. <i>American Journal of Public Health</i> , 2001, 91, 84-92.	2.7	59
184	Treatment of coexisting diabetes and hypertension. <i>Current Cardiology Reports</i> , 2001, 3, 498-503.	2.9	3
185	The role of angiotensinconverting enzyme inhibitors in the treatment of hypertension. <i>Current Cardiology Reports</i> , 2001, 3, 511-518.	2.9	8
186	Drugs for cardiovascular risk reduction in the diabetic patient. <i>Current Diabetes Reports</i> , 2001, 1, 133-139.	4.2	5
187	Treatment of hypertension in diabetic patients with nephropathy. <i>Current Diabetes Reports</i> , 2001, 1, 251-260.	4.2	6
188	Problems in the control of systolic blood pressure. <i>Current Hypertension Reports</i> , 2001, 3, 173-174.	3.5	0
189	What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?. <i>Current Hypertension Reports</i> , 2001, 3, 422-428.	3.5	11

#	ARTICLE	IF	CITATIONS
190	Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes. <i>Current Hypertension Reports</i> , 2001, 3, 340-349.	3.5	4
191	Diabetic nephropathy: Prevention and treatment. <i>Kidney International</i> , 2001, 60, 2041-2055.	5.2	187
192	The NEPI Antidiabetes Study (NANSY). 1: Short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose*. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3, 443-451.	4.4	11
193	Circulating plasma vascular endothelial growth factor and microvascular complications of Type 1 diabetes mellitus: the influence of ACE inhibition. <i>Diabetic Medicine</i> , 2001, 18, 288-294.	2.3	54
194	Augmentation of central arterial pressure in Type 2 diabetes. <i>Diabetic Medicine</i> , 2001, 18, 374-380.	2.3	95
195	An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). <i>Diabetic Medicine</i> , 2001, 18, 438-444.	2.3	18
196	Use of beta-blockers in obesity hypertension: potential role of weight gain. <i>Obesity Reviews</i> , 2001, 2, 275-280.	6.5	78
197	Betablocker treatment in diabetes mellitus. <i>Journal of Internal Medicine</i> , 2001, 250, 11-17.	6.0	48
198	The regional distribution of diabetic retinopathy lesions may reflect risk factors for progression of the disease. <i>Acta Ophthalmologica</i> , 2001, 79, 501-505.	0.3	29
199	Hypertension in diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2001, 18, 197-200.	0.2	1
200	Does opportunistic screening for diabetic retinopathy result in timely and appropriate referral?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2001, 18, 265-268.	0.2	2
202	The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2001, 345, 870-878.	27.0	2,926
203	Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2001, 345, 851-860.	27.0	5,332
204	Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. <i>Clinical Cardiology</i> , 2001, 24, 151-158.	1.8	103
205	The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy. <i>Journal of Human Hypertension</i> , 2001, 15, 837-839.	2.2	3
206	Current therapeutic algorithms for type 2 diabetes. <i>Clinical Cornerstone</i> , 2001, 4, 38-49.	0.7	4
207	Diabetes. <i>British Medical Bulletin</i> , 2001, 59, 159-172.	6.9	4
209	Slowing the Progression of Renal Disease in Diabetic Patients. <i>Annals of Pharmacotherapy</i> , 2001, 35, 452-463.	1.9	15

#	ARTICLE	IF	CITATIONS
210	Subclinical States of Glucose Intolerance and Risk of Death in the U.S.. Diabetes Care, 2001, 24, 447-453.	8.6	207
211	Baseline Characteristics of the Diabetic Participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care, 2001, 24, 654-658.	8.6	40
214	New Techniques for the Evaluation of Diabetic Neuropathies. Diabetes Technology and Therapeutics, 2001, 3, 1-8.	4.4	0
215	Cardiovascular Drug Use and Hospitalizations Attributable to Type 2 Diabetes. Diabetes Care, 2001, 24, 1428-1432.	8.6	11
216	Diabetes Screening in Canada (DIASCAN) Study: Prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care, 2001, 24, 1038-1043.	8.6	77
217	Review: UKPDS odyssey " 2001. British Journal of Diabetes and Vascular Disease, 2001, 1, 14-21.	0.6	2
218	Review: Promise of prevention and reversal of target organ involvement in hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S4-S9.	1.7	6
219	Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, 170-173.	1.7	1
220	Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension, 2001, 37, 19-27.	2.7	112
221	Blood Pressure Control and Benefits of Antihypertensive Therapy. Hypertension, 2001, 38, 537-542.	2.7	36
222	Reduced Cardiovascular Morbidity and Mortality in Hypertensive Diabetic Patients on First-Line Therapy With an ACE Inhibitor Compared With a Diuretic/ β -Blocker-Based Treatment Regimen. Diabetes Care, 2001, 24, 2091-2096.	8.6	230
223	Hypothesis: β -Adrenergic Receptor Blockers and Weight Gain. Hypertension, 2001, 37, 250-254.	2.7	278
224	Longitudinal Analysis of Blood Pressure, Lipid, and Glycemic Control in Diabetic Patients With Nephropathy Attending a Hospital Outpatient Clinic and Their Relationship to Renal Function, Mortality, and Cardiovascular Morbidity. Diabetes Care, 2001, 24, 789-790.	8.6	9
225	GENERAL CARDIOLOGY: Diabetic heart disease: clinical considerations. British Heart Journal, 2001, 85, 463-469.	2.1	29
226	Diabetics with Hypertension Not Controlled with ACE Inhibitors: Alternate Therapies. Angiology, 2001, 52, 469-475.	1.8	14
227	Local Hemodynamic Changes in Hypertension. Hypertension, 2001, 38, 1388-1394.	2.7	33
228	Review: intensive blood pressure control and drugs reduce morbidity and mortality in hypertension and diabetes mellitus. Evidence-Based Medicine, 2001, 6, 44-44.	0.6	3
229	Therapeutic Benefits of ACE Inhibitors and Other Antihypertensive Drugs in Patients With Type 2 Diabetes. Diabetes Care, 2001, 24, 177-178.	8.6	9

#	ARTICLE	IF	CITATIONS
230	Meta-analysis of Hypertension Trials in Diabetic Patients: Response to Parving and Rossing. <i>Diabetes Care</i> , 2001, 24, 178-180.	8.6	0
231	Effect of the Angiotensin II Receptor Antagonist Valsartan on Lipid Profile and Glucose Metabolism in Patients with Hypertension. <i>Journal of International Medical Research</i> , 2001, 29, 270-279.	1.0	30
232	Common Drug Pathways and Interactions. <i>Diabetes Spectrum</i> , 2002, 15, 249-255.	1.0	10
233	Review: Angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in diabetic renal disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2002, 2, 81-84.	0.6	0
234	Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. <i>Vascular Medicine</i> , 2002, 7, 35-43.	1.5	244
235	The prevalence of calcified carotid artery atheromas on the panoramic radiographs of patients with type 2 diabetes mellitus. <i>Journal of the American Dental Association</i> , 2002, 133, 1516-1523.	1.5	45
237	Renoprotection: A Matter of Blood Pressure Reduction or Agent-Characteristics?. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, S202-S207.	6.1	14
239	Culturally Competent Dietary Education for Southern Rural African Americans With Diabetes. <i>The Diabetes Educator</i> , 2002, 28, 245-257.	2.5	36
240	Review: Thirty-seven years with diabetic retinopathy. <i>British Journal of Diabetes and Vascular Disease</i> , 2002, 2, 452-456.	0.6	0
242	Self-monitoring of glucose levels for people with type 2 diabetes. <i>British Journal of Community Nursing</i> , 2002, 7, 41-46.	0.4	17
243	Hypertension and diabetes. <i>Journal of Human Hypertension</i> , 2002, 16, S56-S60.	2.2	12
244	Respiratory Uncoupling Lowers Blood Pressure Through a Leptin-Dependent Mechanism in Genetically Obese Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 961-968.	2.4	73
246	ACE Inhibitor as One of Several Possible First-Line Agents Is Reasonable for Diabetic Patients With Hypertension. <i>Diabetes Care</i> , 2002, 25, 1488-1489.	8.6	2
248	Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, S224-S229.	6.1	47
249	Review: Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, 79-89.	1.7	9
250	Is It the Agent or the Blood Pressure Level that Matters for Renal Protection in Chronic Nephropathies?. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, S196-S201.	6.1	18
252	Obesity, Hypertension, and Insulin Resistance. <i>Diabetes Care</i> , 2002, 25, 2088-2097.	8.6	53
253	Eplerenone – A Novel Selective Aldosterone Blocker. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1567-1576.	1.9	40

#	ARTICLE	IF	CITATIONS
254	Clinical Trial Evidence for Cardiovascular Risk Reduction in Type 2 Diabetes. <i>Journal of Cardiovascular Nursing</i> , 2002, 16, 24-43.	1.1	6
255	Recent developments in the treatment of obesity-related hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 497-502.	2.0	11
256	Rationale and design of HOMED-BP Study: Hypertension Objective treatment based on Measurement by Electrical Devices of Blood Pressure Study. <i>Blood Pressure Monitoring</i> , 2002, 7, 77-82.	0.8	54
257	Prevalence, awareness, treatment and control of hypertension in a Canarian population. Relationship with glucose tolerance categories. The GuÃa Study. <i>Journal of Hypertension</i> , 2002, 20, 1965-1971.	0.5	16
258	Hypertension and diabetes. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 221-228.	2.0	64
259	Systolic and diastolic blood pressure control in antihypertensive drug trials. <i>Journal of Hypertension</i> , 2002, 20, 1461-1464.	0.5	233
260	Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. <i>Journal of Hypertension</i> , 2002, 20, 1231-1237.	0.5	32
261	Antihypertensive treatment in patients with type-2 diabetes mellitus. <i>Journal of Hypertension</i> , 2002, 20, 2099-2110.	0.5	121
262	Perioperative β_2 -adrenoceptor blockade in major non-cardiac surgery. <i>Southern African Journal of Anaesthesia and Analgesia</i> , 2002, 8, 30-35.	0.3	1
263	Renal Dysfunction Complicating the Treatment of Hypertension. <i>New England Journal of Medicine</i> , 2002, 347, 1256-1261.	27.0	286
264	The Treatment of Hypertension in Adult Patients With Diabetes. <i>Diabetes Care</i> , 2002, 25, 134-147.	8.6	280
265	The new era in managing type 2 diabetes. <i>American Journal of Medicine</i> , 2002, 112, 243.	1.5	0
266	Vascular and cardiac benefits of angiotensin receptor blockers. <i>American Journal of Medicine</i> , 2002, 113, 409-418.	1.5	119
267	Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. <i>American Journal of Ophthalmology</i> , 2002, 134, 749-760.	3.3	94
268	Factors Influencing the Systolic Blood Pressure Response to Drug Therapy. <i>Journal of Clinical Hypertension</i> , 2002, 4, 35-40.	2.0	20
269	Should β_2 Blockers Be Used in the Treatment of Hypertension in the Elderly?. <i>Journal of Clinical Hypertension</i> , 2002, 4, 286-294.	2.0	7
270	Clinical Impact of Renin-Angiotensin System Blockade: Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Antagonists. <i>Journal of Clinical Hypertension</i> , 2002, 4, 11-31.	2.0	5
271	ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?. <i>Journal of Clinical Hypertension</i> , 2002, 4, 420-440.	2.0	30

#	ARTICLE	IF	CITATIONS
272	Update on the Management of Diabetes and Hypertension. Journal of Clinical Hypertension, 2002, 4, 3-10.	2.0	9
273	Optimizing the diabetic formulary: beyond aspirin and insulin. Journal of the American College of Cardiology, 2002, 40, 652-661.	2.8	26
274	Prevention of heart failure. Journal of Cardiac Failure, 2002, 8, 333-346.	1.7	84
275	The Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in the Management of Diabetic Complications. Drugs, 2002, 62, 2007-2012.	10.9	13
276	Nephropathy in Patients with Type 2 Diabetes. New England Journal of Medicine, 2002, 346, 1145-1151.	27.0	537
277	Antagonistas de los receptores de la angiotensina II. Una revisi3n farmacoterap4utica. Hipertension Y Riesgo Vascular, 2002, 19, 129-138.	0.6	1
278	Documento de consenso 2002 sobre pautas e detecci3n, prevenci3n y tratamiento e la nefropat4a diab4tica en Espa1a. Semergen, 2002, 28, 631-638.	0.5	8
279	Pautas de detecci3n, prevenci3n y tratamiento de la nefropat4a diab4tica en espa1a. Hipertension Y Riesgo Vascular, 2002, 19, 412-420.	0.6	1
281	Interpreting the Risks of Diabetic Renal Disease: Perspectives of those Most at Risk. Psychology and Health, 2002, 17, 33-50.	2.2	4
282	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, The, 2002, 359, 1004-1010.	13.7	1,520
283	Renoprotection with antihypertensive agents. Lancet, The, 2002, 359, 1693.	13.7	0
284	Blood pressure and cardiovascular risk in the HOPE study. Lancet, The, 2002, 359, 2118.	13.7	2
285	Blood pressure and cardiovascular risk in the HOPE study. Lancet, The, 2002, 359, 2117-2118.	13.7	6
286	Angiotensin II receptor blockade in diabetic nephropathy. American Journal of Hypertension, 2002, 15, 468-471.	2.0	19
287	Ace inhibition and cardiovascular mortality and morbidity in essential hypertension: The end of the search or a need for further investigations?. American Journal of Hypertension, 2002, 15, 367-371.	2.0	20
288	Life after LIFE. Cardiovascular benefits of angiotensin II receptor blockade in older people with essential hypertension, left ventricular hypertrophy and diabetes mellitus. European Journal of Internal Medicine, 2002, 13, 353-355.	2.2	2
289	Angiotensin receptor blockersâ€”finally the evidence is coming in: IDNT and RENAAL. International Journal of Cardiology, 2002, 86, 325-326.	1.7	0
296	Hypertension in special populations. Cardiology Clinics, 2002, 20, 303-319.	2.2	27

#	ARTICLE	IF	CITATIONS
297	Targeting the Renin-Angiotensin System in Patients with Renal Disease. Journal of the Royal Society of Medicine, 2002, 95, 391-397.	2.0	3
298	Diabetic Renal Disease in African Americans. American Journal of the Medical Sciences, 2002, 323, 78-84.	1.1	31
299	Diabetes and Hypertension. Medicine, 2002, 30, 30-32.	0.4	2
301	Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive Type 2 diabetic patients. Journal of Diabetes and Its Complications, 2002, 16, 377-381.	2.3	25
302	Treatment of hypertension from volume to vasoconstriction: The ACE up your sleeve. Seminars in Vascular Surgery, 2002, 15, 225-236.	2.8	0
303	An introduction to new advances in diabetes. Diabetes/Metabolism Research and Reviews, 2002, 18, S1-S6.	4.0	4
304	Prevention of heart failure. Current Cardiology Reports, 2002, 4, 194-199.	2.9	7
305	The use of ACE inhibitors on diabetic patients without renal disease. Current Diabetes Reports, 2002, 2, 21-25.	4.2	2
306	Cardiovascular risk factors in diabetic patients with hypertension. Current Diabetes Reports, 2002, 2, 263-266.	4.2	2
307	The choice of antihypertensive drugs in patients with diabetes: Angiotensin II and beyond. Current Diabetes Reports, 2002, 2, 423-430.	4.2	0
308	Blood pressure control—Effects on diabetic nephropathy progression: How low does blood pressure have to be?. Current Diabetes Reports, 2002, 2, 530-538.	4.2	5
309	Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Current Hypertension Reports, 2002, 4, 185-190.	3.5	17
310	Carcinogenicity of antihypertensive therapy. Current Hypertension Reports, 2002, 4, 195-201.	3.5	24
311	Sympathetic nervous system function in renal hypertension. Current Hypertension Reports, 2002, 4, 229-236.	3.5	22
312	Blood pressure-independent impact of antihypertensive agents on cardiovascular and renal disease. Current Hypertension Reports, 2002, 4, 445-452.	3.5	5
313	Managing the hypertensive patient with ischemic heart disease. Current Hypertension Reports, 2002, 4, 350-357.	3.5	0
314	Optimizing blood pressure control in the obese patient. Current Hypertension Reports, 2002, 4, 358-362.	3.5	5
315	Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Current Hypertension Reports, 2002, 4, 387-393.	3.5	42

#	ARTICLE	IF	CITATIONS
316	Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?. <i>Current Hypertension Reports</i> , 2002, 4, 290-297.	3.5	1
317	The cardioprotective role of beta-blockers in patients with diabetes mellitus. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002, 27, 233-242.	1.5	14
318	Blood pressure control in patients with type 2 diabetes and hypertension. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 81-88.	4.4	4
319	The [C282Y/wt] heterozygous HFE genotype is associated with lower blood pressure and HDL-cholesterol in Type 2 diabetes. <i>Diabetic Medicine</i> , 2002, 19, 796-796.	2.3	0
320	Body weight changes and the A-6G polymorphism of the angiotensinogen gene. <i>International Journal of Obesity</i> , 2002, 26, 1173-1178.	3.4	19
321	The reno-protective role of AT1-receptor blockers. <i>Journal of Human Hypertension</i> , 2002, 16, S52-S58.	2.2	22
322	A population-based European cohort study of persistence in newly diagnosed hypertensive patients. <i>Journal of Human Hypertension</i> , 2002, 16, 569-575.	2.2	99
323	Hypertension and the eye: changing perspectives. <i>Journal of Human Hypertension</i> , 2002, 16, 667-675.	2.2	77
324	A Comparative Randomized and Placebo-controlled Short-term Trial of Aspirin and Dipyridamole for Overt Type-2 Diabetic Nephropathy. <i>Scandinavian Journal of Urology and Nephrology</i> , 2002, 36, 145-148.	1.4	30
325	The Cost of Diabetes Type II in Europe The CODE-2 Study. <i>Diabetologia</i> , 2002, 45, S1-S4.	6.3	97
326	Evaluation of risk factors for development of complications in Type II diabetes in Europe. <i>Diabetologia</i> , 2002, 45, S23-S28.	6.3	182
328	Der Arzneimittelgebrauch und die Compliance von Patienten mit Diabetes mellitus in der Allgemeinarztpraxis nach Arztangaben. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2003, 11, 337-347.	1.6	0
330	Use of ACE inhibitors for secondary prevention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2003, 5, 51-61.	0.9	1
331	The J-curve in hypertension. <i>Current Cardiology Reports</i> , 2003, 5, 441-452.	2.9	34
332	Proteinuria in diabetic nephropathy: Treatment and evolution. <i>Current Diabetes Reports</i> , 2003, 3, 497-504.	4.2	28
333	Are low target blood pressure goals justified in persons with diabetes mellitus?. <i>Current Hypertension Reports</i> , 2003, 5, 231-238.	3.5	3
334	Lessons from trials in hypertensive type 2 diabetic patients. <i>Current Hypertension Reports</i> , 2003, 5, 322-328.	3.5	1
335	Angiotensin II and the glomerulus: Focus on diabetic kidney disease. <i>Current Hypertension Reports</i> , 2003, 5, 172-180.	3.5	5

#	ARTICLE	IF	CITATIONS
336	Isolated systolic hypertension and the risk of vascular disease. <i>Current Hypertension Reports</i> , 2003, 5, 372-379.	3.5	18
337	Under-prescribing of cardiovascular therapies for diabetes in primary care. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 835-841.	1.9	26
338	Carotid stents: is the gold standard ready for change?. <i>Journal of Vascular Nursing</i> , 2003, 21, 132-138.	0.7	1
339	β 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. <i>European Journal of Pharmacology</i> , 2003, 460, 19-26.	3.5	40
340	Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. <i>Journal of Cellular Physiology</i> , 2003, 196, 171-179.	4.1	115
341	Treatment of diabetic nephropathy in its early stages. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 101-114.	4.0	19
342	Variation in diabetes care by age: opportunities for customization of care. <i>BMC Family Practice</i> , 2003, 4, 16.	2.9	28
343	Pathogenesis of diabetic retinopathy and the renin-angiotensin system. <i>Ophthalmic and Physiological Optics</i> , 2003, 23, 495-501.	2.0	38
344	Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). <i>Kidney International</i> , 2003, 63, 225-232.	5.2	1,429
345	Guidelines for Improving the Care of the Older Person with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 265-280.	2.6	625
346	Lipoprotein abnormalities and their consequences for patients with Type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, S19-27.	4.4	162
347	Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, 214-222.	4.4	53
348	Pathophysiological implications of insulin resistance on vascular endothelial function. <i>Diabetic Medicine</i> , 2003, 20, 255-268.	2.3	234
349	Prediction of cardiovascular risk in people with diabetes. <i>Diabetic Medicine</i> , 2003, 20, 515-527.	2.3	29
350	The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. <i>Diabetic Medicine</i> , 2003, 20, 607-621.	2.3	75
351	Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. <i>Diabetic Medicine</i> , 2003, 20, 972-987.	2.3	44
352	Observational study of ACE inhibitor prescribing habits of diabetes physicians in the UK. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 21-24.	0.2	1
353	Hypertension in diabetes: what's new, what's true, what's next?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 247-254.	0.2	3

#	ARTICLE	IF	CITATIONS
354	Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. <i>Journal of Human Hypertension</i> , 2003, 17, 37-44.	2.2	48
355	Protección del riesgo vascular del paciente diabético hipertenso. <i>Hipertension Y Riesgo Vascular</i> , 2003, 20, 127-135.	0.6	0
357	Outcome studies in diabetic nephropathy. <i>Seminars in Nephrology</i> , 2003, 23, 255-271.	1.6	18
359	Treatment of Lupus Nephritis. <i>Drugs</i> , 2003, 63, 257-274.	10.9	12
360	Current Management Strategies for Coexisting Diabetes Mellitus and Obesity. <i>Drugs</i> , 2003, 63, 1165-1184.	10.9	76
361	Heart failure in diabetic patients: Utility of β -blockade. <i>Journal of Cardiac Failure</i> , 2003, 9, 333-344.	1.7	22
362	Perspectives on diabetic retinopathy. <i>American Journal of Ophthalmology</i> , 2003, 136, 122-135.	3.3	251
363	The Differences Between ACE Inhibitor-Treated and Calcium Channel Blocker-Treated Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2003, 5, 337-344.	2.0	2
364	Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials. <i>Journal of Clinical Hypertension</i> , 2003, 5, 66-75.	2.0	26
365	Meeting the Challenge to Improve the Treatment of Hypertension in Blacks. <i>Journal of Clinical Hypertension</i> , 2003, 5, 393-401.	2.0	17
366	Response to Six Classes of Antihypertensive Medications by Body Mass Index in a Randomized Controlled Trial. <i>Journal of Clinical Hypertension</i> , 2003, 5, 197-201.	2.0	8
367	Hypertension in the Metabolic Syndrome and Diabetes: Pathogenesis, Clinical Studies, and Treatment. <i>Journal of Clinical Hypertension</i> , 2003, 5, 3-10.	2.0	9
368	Diabetes and Vascular Disease. <i>Circulation</i> , 2003, 108, 1655-1661.	1.6	397
369	Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. <i>Lancet</i> , 2003, 362, 1527-1535.	13.7	2,300
370	Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: A review of the clinical trial evidence. <i>Clinical Therapeutics</i> , 2003, 25, 3044-3064.	2.5	35
371	Coronary artery disease: New insights into the pathophysiology, prevalence and early detection of a monster menace. <i>Seminars in Ultrasound, CT and MRI</i> , 2003, 24, 114-122.	1.5	3
372	Cardiovascular disease in patients who have diabetes. <i>Cardiology Clinics</i> , 2003, 21, 399-413.	2.2	29
373	A Comparison of Outcomes with Angiotensin-Converting Enzyme Inhibitors and Diuretics for Hypertension in the Elderly. <i>New England Journal of Medicine</i> , 2003, 348, 583-592.	27.0	1,078

#	ARTICLE	IF	CITATIONS
374	Prevention and Treatment of Diabetic Nephropathy in Older Patients. <i>Drugs and Aging</i> , 2003, 20, 419-435.	2.7	2
375	β-Blockers after Acute Myocardial Infarction in Elderly Patients with Diabetes Mellitus. <i>Drugs and Aging</i> , 2003, 20, 13-22.	2.7	7
376	Cost Effectiveness of Diabetes Mellitus Management Programs. <i>Disease Management and Health Outcomes</i> , 2003, 11, 439-453.	0.4	8
377	What are the best first-line antihypertensives: answers and more questions from the ALLHAT study. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 879-885.	4.1	1
378	Diabetic Retinopathy and Diabetic Macular Edema. <i>Diabetes Care</i> , 2003, 26, 2653-2664.	8.6	695
379	Preventing Macrovascular Disease in Patients with Type 2 Diabetes Mellitus. <i>American Journal of Cardiovascular Drugs</i> , 2003, 3, 283-297.	2.2	18
380	Implications of the LIFE trial. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 871-877.	4.1	6
381	Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. <i>Hypertension</i> , 2003, 42, 1206-1252.	2.7	11,852
382	Review: The management of stable angina in diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2003, 3, 18-25.	0.6	3
383	The Effects of Transdermal Estradiol Alone or with Cyclical Dydrogesterone on Markers of Cardiovascular Disease Risk in Postmenopausal Women with Type 2 Diabetes: A Pilot Study. <i>Angiology</i> , 2003, 54, 391-399.	1.8	30
384	Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). <i>Hypertension</i> , 2003, 41, 431-436.	2.7	154
385	Review: Early renal involvement in Type 1 diabetes mellitus – Part 2: ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 17-26.	1.7	4
386	Diabetic Nephropathy. <i>Diabetes Care</i> , 2003, 26, S94-S98.	8.6	209
388	Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 74-79.	1.7	5
389	The Diabetes Prevention Program and Its Global Implications. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S103-S107.	6.1	46
390	Review: Hypertension in diabetes: a perspective from clinical pharmacology. <i>British Journal of Diabetes and Vascular Disease</i> , 2003, 3, 252-256.	0.6	0
391	Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1543-1550.	1.8	3
392	Considerations for Diabetes Translational Research in Real-World Settings. <i>Diabetes Care</i> , 2003, 26, 2670-2674.	8.6	145

#	ARTICLE	IF	CITATIONS
393	Improving Diabetes Processes of Care in Managed Care. <i>Diabetes Care</i> , 2003, 26, 2722-2727.	8.6	54
394	Implications of the United Kingdom Prospective Diabetes Study. <i>Diabetes Care</i> , 2003, 26, S28-S32.	8.6	184
395	Extended-Release Metoprolol Succinate in Chronic Heart Failure. <i>Annals of Pharmacotherapy</i> , 2003, 37, 701-710.	1.9	14
396	Diabetes Mellitus and Heart Failure. <i>The American Heart Hospital Journal</i> , 2003, 1, 273-280.	0.2	14
398	What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. <i>BMJ: British Medical Journal</i> , 2003, 327, 266-0.	2.3	63
399	The ALLHAT trial. <i>Journal of Hypertension</i> , 2003, 21, 229-232.	0.5	16
400	Pharmacologic therapy for diabetic retinopathy. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 239-250.	2.4	21
401	Converting Enzyme Inhibitor or AT 1 -Receptor Blocker for Decreasing Long-Term Mortality in Patients With Stroke History and Renal Dysfunction?. <i>Stroke</i> , 2003, 34, 8-9.	2.0	6
402	Evaluation and medical treatment of peripheral arterial disease. <i>Current Opinion in Cardiology</i> , 2003, 18, 436-443.	1.8	17
403	Trends in Management of Type 2 Diabetes. , 2003, 13, S1-S21.		2
404	Diabetes Mellitus and Hypertension: A Mandate for Intense Treatment According to New Guidelines. <i>American Journal of Therapeutics</i> , 2003, 10, 363-369.	0.9	6
405	The ALLHAT study. <i>Journal of Hypertension</i> , 2003, 21, 453-454.	0.5	30
406	Preventing diabetic retinopathy through control of systemic factors. <i>Current Opinion in Ophthalmology</i> , 2003, 14, 389-394.	2.9	20
407	Clinical implications of PROGRESS: questions and answers. <i>Journal of Hypertension</i> , 2003, 21, S21-S24.	0.5	1
408	International Society of Hypertension (ISH). <i>Journal of Hypertension</i> , 2003, 21, 651-663.	0.5	45
409	Diabetes and Heart Disease. <i>Cardiology in Review</i> , 2003, 11, 262-274.	1.4	28
410	Emerging drugs for renal failure. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 389-435.	2.4	11
411	Remission and Regression of Diabetic Nephropathy. <i>Hypertension Research</i> , 2003, 26, 515-519.	2.7	27

#	ARTICLE	IF	CITATIONS
412	Diabetic nephropathy in type 2 diabetes mellitus: risk factors and prevention. Arquivos Brasileiros De Endocrinologia E Metabologia, 2003, 47, 207-219.	1.3	17
413	Proteinuria and Microalbuminuria in Adults: Significance, Evaluation, and Treatment. Southern Medical Journal, 2004, 97, 969-979.	0.7	24
414	Hypertensive Therapy: Part II. Circulation, 2004, 109, 3081-3088.	1.6	30
415	Classical Anti-oxidants (Scavengers) versus Biological Anti-oxidants (Suppressors of ROS Generation): ANovel Way to Explain the Anti-oxidant Paradox. Metabolic Syndrome and Related Disorders, 2004, 2, 155-159.	1.3	3
416	Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 592 T Hypertension, and Renal Disease. Diabetes Care, 2004, 27, 1897-1903.	8.6	91
418	Too much of a good thing: 2004 guidance from NICE and BHS-IV on hypertension in diabetes. British Journal of Diabetes and Vascular Disease, 2004, 4, 365-368.	0.6	3
419	Angiotensin-Converting Enzyme Inhibitors versus AT1 Receptor Antagonist in Cardiovascular and Renal Protection: The case for AT1 Receptor Antagonist. Journal of the American Society of Nephrology: JASN, 2004, 15, 71S-76.	6.1	30
420	Hypertension and the Vascular Patient. Vascular and Endovascular Surgery, 2004, 38, 103-119.	0.7	3
421	Improving Efficacy of Diabetes Management Using Treatment Algorithms in a Mainly Hispanic Population. Diabetes Care, 2004, 27, 1638-1646.	8.6	34
422	Effect of Angiotensin-Converting Enzyme Inhibition on Survival in 3773 Chinese Type 2 Diabetic Patients. Hypertension, 2004, 44, 294-299.	2.7	33
423	Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment. Journal of the American Society of Nephrology: JASN, 2004, 15, 6S-11.	6.1	21
425	Case Study: Treating Hypertension in Patients With Diabetes. Clinical Diabetes, 2004, 22, 137-138.	2.2	2
427	CALCIUM CHANNEL BLOCKERS IN THE PREVENTION OF END STAGE RENAL DISEASE: A REVIEW. Acta Clinica Belgica, 2004, 59, 44-56.	1.2	10
428	Diabetic Retinopathy. Diabetes Care, 2004, 27, 2540-2553.	8.6	575
429	Blood Glucose and Risk of Cardiovascular Disease in the Asia Pacific Region. Diabetes Care, 2004, 27, 2836-2842.	8.6	269
430	Clinical skills: empowering people with diabetes to minimize complications. British Journal of Nursing, 2004, 13, 644-651.	0.7	24
431	Blood Pressure and Stroke. Stroke, 2004, 35, 1024-1033.	2.0	238
432	The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. Clinical Trials, 2004, 1, 532-544.	1.6	54

#	ARTICLE	IF	CITATIONS
433	Diabetes: preventing coronary heart disease in a high risk group. <i>British Heart Journal</i> , 2004, 90, iv18-iv21.	2.1	14
434	From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H435-H446.	3.2	220
435	What is the impact of PRIME on real-life diabetic nephropathy?. <i>International Journal of Clinical Practice</i> , 2004, 58, 268-276.	1.7	2
436	Clinical inertia in the management of Type 2 diabetes metabolic risk factors. <i>Diabetic Medicine</i> , 2004, 21, 150-155.	2.3	145
437	Diabetic renal disease: from recent studies to improved clinical practice. <i>Diabetic Medicine</i> , 2004, 21, 4-17.	2.3	45
438	Screening for glucose intolerance post myocardial infarction. <i>Diabetic Medicine</i> , 2004, 21, 12-13.	2.3	0
439	1. Testing for proteinuria. <i>Nephrology</i> , 2004, 9, S3-S7.	1.6	6
440	Rational pharmacotherapy in the diabetic hypertension: analysis-prescribing patterns in a general hospital in Taiwan. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 547-558.	1.5	5
441	Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy. <i>Eye</i> , 2004, 18, 117-125.	2.1	19
442	The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?. <i>Journal of Human Hypertension</i> , 2004, 18, 461-465.	2.2	22
443	Effects of diabetes on the vascular system: current research evidence and best practice recommendations. <i>Journal of Vascular Nursing</i> , 2004, 22, 2-11.	0.7	10
444	Angiotensin-Converting Enzyme Inhibitors and Stroke Risk: Benefit Beyond Blood Pressure Reduction?. <i>Pharmacotherapy</i> , 2004, 24, 1064-1076.	2.6	16
445	Focusing on Patient-Oriented Evidence that Matters in the Care of Patients with Diabetes Mellitus. <i>Pharmacotherapy</i> , 2004, 24, 295-297.	2.6	2
446	Meta-Analysis of effectiveness or lack thereof of Angiotensin-Converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. <i>American Journal of Cardiology</i> , 2004, 93, 240-243.	1.6	28
447	Practical guidelines to optimize effectiveness of β -blockade in patients postinfarction and in those with chronic heart failure. <i>American Journal of Cardiology</i> , 2004, 93, 69-73.	1.6	4
448	Strategies for managing the diabetic patient. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2004, 18, 631-643.	4.0	23
449	Chemistry and Biochemistry of Type 2 Diabetes. <i>Chemical Reviews</i> , 2004, 104, 1255-1282.	47.7	303
450	Ultrastructural alterations in capillaries of the diabetic hypertensive rat retina: protective effects of ACE inhibition. <i>Diabetologia</i> , 2004, 47, 1196-1201.	6.3	17

#	ARTICLE	IF	CITATIONS
451	Antihypertensive drugs and the kidney. <i>Current Cardiology Reports</i> , 2004, 6, 403-408.	2.9	4
452	Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management. <i>Current Hypertension Reports</i> , 2004, 6, 215-223.	3.5	99
453	Klinischer Einsatz von Beta-Blockern bei kardiovaskulären Indikationen: Neue Therapiestudien. <i>Pharmazie in Unserer Zeit</i> , 2004, 33, 466-475.	0.0	0
454	Ethnicity and prevalence of diabetic complications in elderly patients. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2004, 21, 139-142.	0.2	3
455	Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 139-146.	1.9	35
456	A novel approach to treatment of hypertension in diabetic patients a€“ a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 a€“ rationale and design [ISRCTN55725285]. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2004, 5, 9.	1.5	6
457	Stroke in patients with diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, 268-287.	4.0	93
458	Nephropathy in Diabetes. <i>Diabetes Care</i> , 2004, 27, s79-s83.	8.6	842
459	Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia. <i>Pharmacoeconomics Italian Research Articles</i> , 2004, 6, 81-93.	0.2	15
460	Valsartan, Cardiac Outcome and Blood Pressure Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004, 11, 113-115.	2.2	0
461	Cost-Effective Strategies in the Prevention of Diabetic Nephropathy. <i>Pharmacoeconomics</i> , 2004, 22, 9-28.	3.3	24
462	Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective. <i>Pharmacoeconomics</i> , 2004, 22, 321-341.	3.3	25
463	Blood Pressure and Stroke. <i>Stroke</i> , 2004, 35, 776-785.	2.0	535
464	Prevention and Treatment of the Metabolic Syndrome. <i>Angiology</i> , 2004, 55, 589-612.	1.8	121
465	La microalbuminuria como factor de riesgo cardiovascular. <i>Semergen</i> , 2004, 30, 110-113.	0.5	0
466	Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations. <i>Cardiology Clinics</i> , 2004, 22, 553-568.	2.2	40
467	Los diuréticos son los fármacos de primera elección en el tratamiento de la hipertensión arterial. <i>Hipertension Y Riesgo Vascular</i> , 2004, 21, 466-474.	0.6	0
468	¿Deben ser considerados los diuréticos como fármacos de uso prácticamente exclusivo en el tratamiento inicial del hipertenso?. <i>Hipertension Y Riesgo Vascular</i> , 2004, 21, 475-481.	0.6	0

#	ARTICLE	IF	CITATIONS
471	Los antagonistas de los receptores de angiotensina II tienen ventajas sobre los inhibidores de la enzima de conversi3n de la angiotensina. Hipertension Y Riesgo Vascul ar, 2004, 21, 78-83.	0.6	0
472	Endothelial dysfunction and hypertension in diabetes mellitus. Medical Clinics of North America, 2004, 88, 911-931.	2.5	35
473	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. Revista Espanola De Cardiologia, 2004, 57, 1213-1232.	1.2	8
474	Target organ involvement in hypertension: a realistic promise of prevention and reversal. Medical Clinics of North America, 2004, 88, 209-221.	2.5	20
475	Diabetes Mellitus: Pathogenesis and Treatment Strategies. Journal of Medicinal Chemistry, 2004, 47, 4113-4117.	6.4	173
476	Slowing the Progression of Adult Chronic Kidney Disease. Drugs, 2004, 64, 2273-2289.	10.9	27
477	Hypoglycaemia in Elderly Patients with Diabetes Mellitus. Drugs and Aging, 2004, 21, 511-530.	2.7	137
478	Cardiovascular Safety of ??2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease. Drugs and Aging, 2004, 21, 405-414.	2.7	70
479	Treatment of metabolic syndrome. Expert Review of Cardiovascular Therapy, 2004, 2, 213-228.	1.5	67
480	Cardiovascular risk factors in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2004, 65, 125-133.	2.8	37
481	New-onset diabetes after transplantation. Journal of Heart and Lung Transplantation, 2004, 23, S194-S201.	0.6	101
482	Coronary artery disease: new insights into the pathophysiology, prevalence, and early detection of a monster menace. Seminars in Ultrasound, CT and MRI, 2004, 25, 113-121.	1.5	8
483	The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism: Clinical and Experimental, 2004, 53, 550-555.	3.4	91
484	Are calcium antagonists beneficial in diabetic patients with hypertension?. American Journal of Medicine, 2004, 116, 44-49.	1.5	28
485	The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. American Journal of Medicine, 2004, 116, 263-272.	1.5	301
486	Case management for patients with poorly controlled diabetes: a randomized trial. American Journal of Medicine, 2004, 116, 732-739.	1.5	116
489	Tratamiento farmacol3gico de la hipertensi3n arterial. Medicine, 2004, 9, 1481-1493.	0.0	0
490	Atenolol in hypertension: is it a wise choice?. Lancet, The, 2004, 364, 1684-1689.	13.7	503

#	ARTICLE	IF	CITATIONS
491	Renoprotective Effect of Losartan in Comparison to Amlodipine in Patients with Chronic Kidney Disease and Hypertension-a Report of the Japanese Losartan Therapy Intended for the Global Renal Protection Hypertensive Patients (JLIGHT) Study. <i>Hypertension Research</i> , 2004, 27, 21-30.	2.7	69
492	Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes. <i>Journal of Hypertension</i> , 2004, 22, 1613-1622.	0.5	127
493	Hypertension: A Clinical Pharmacist's Synopsis of JNC 7. <i>American Journal of Pharmaceutical Education</i> , 2004, 68, 71.	2.1	1
494	Pharmacotherapy for diabetic retinopathy. <i>Current Opinion in Ophthalmology</i> , 2004, 15, 508-518.	2.9	56
495	Latin American consensus on diabetes mellitus and hypertension. <i>Journal of Hypertension</i> , 2004, 22, 2229-2241.	0.5	18
496	Does comorbidity explain trends in prescribing of newer antihypertensive agents?. <i>Journal of Hypertension</i> , 2004, 22, 2209-2215.	0.5	13
497	Type 2 Diabetes and Chronic Systolic Heart Failure. <i>Journal of Cardiovascular Nursing</i> , 2004, 19, S35-S44.	1.1	8
498	CARDIOVASCULAR PREVENTION IN TYPE 2 DIABETIC PATIENTS: REVIEW OF EFFICACIOUS TREATMENTS. <i>Acta Clinica Belgica</i> , 2004, 59, 329-339.	1.2	3
499	Cardiovascular Effects of β_2 -Agonists in Patients With Asthma and COPD. <i>Chest</i> , 2004, 125, 2309-2321.	0.8	501
500	Regular screening in type 2 diabetes. <i>Postgraduate Medicine</i> , 2004, 115, 19-27.	2.0	7
501	Implementation and Evaluation of Australian Pharmacists's™ Diabetes Care Services. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, 455-466.	1.5	62
502	Management of the Metabolic Syndrome. <i>American Journal of the Medical Sciences</i> , 2005, 330, 343-351.	1.1	15
503	Diabetic Nephropathy. <i>Diabetes Care</i> , 2005, 28, 745-751.	8.6	36
504	Treating Hypertension With Cardioprotective Therapies. <i>Journal of Cardiovascular Nursing</i> , 2005, 20, 354-364.	1.1	25
505	Primary and secondary prevention of chronic kidney disease. <i>Journal of Hypertension</i> , 2005, 23, 1771-1776.	0.5	8
506	Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. <i>Journal of Hypertension</i> , 2005, 23, 463-473.	0.5	259
507	VALUE and supremacy of blood pressure control for cardiovascular protection. <i>Journal of Hypertension</i> , 2005, 23, 899-900.	0.5	0
508	Evidence-based medicine in hypertension: what type of evidence?. <i>Journal of Hypertension</i> , 2005, 23, 1113-1120.	0.5	58

#	ARTICLE	IF	CITATIONS
509	Antihypertensive agents for preventing diabetic kidney disease. , 2005, , CD004136.		43
510	A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. <i>Kidney International</i> , 2005, 68, 285-292.	5.2	63
511	Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?. <i>Journal of Human Hypertension</i> , 2005, 19, 111-117.	2.2	21
512	Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal. <i>International Journal of Clinical Practice</i> , 2005, 59, 1345-1355.	1.7	123
513	Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies. <i>American Journal of Cardiology</i> , 2005, 96, 1530-1536.	1.6	106
514	Renal Histopathological Lesions After Orthotopic Liver Transplantation (OLT). <i>American Journal of Transplantation</i> , 2005, 5, 1120-1129.	4.7	142
515	Thiazolidinediones Benefits on microvascular complications of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2005, 19, 168-177.	2.3	33
516	Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers for Prevention and Treatment of Nephropathy Associated with Type 2 Diabetes Mellitus. <i>Pharmacotherapy</i> , 2005, 25, 1602-1620.	2.6	21
517	Can the Renin-Angiotensin System Protect Against Stroke? A Focus on Angiotensin II Receptor Blockers. <i>Pharmacotherapy</i> , 2005, 25, 531-539.	2.6	12
519	The changing epidemiology of diabetic microangiopathy in type 1 diabetes. <i>Diabetologia</i> , 2005, 48, 1439-1444.	6.3	84
520	Treatment of hypertension and adherence to treatment guidelines in clinical practice: An Italian study. <i>Advances in Therapy</i> , 2005, 22, 96-106.	2.9	9
521	Prevention of coronary heart disease in diabetes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 259-271.	0.9	3
522	Clinical Trials Report. <i>Current Hypertension Reports</i> , 2005, 7, 204-205.	3.5	2
523	Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care. <i>Current Hypertension Reports</i> , 2005, 7, 439-449.	3.5	8
524	Does ALLHAT change the management of hypertension in chronic kidney disease?. <i>Current Hypertension Reports</i> , 2005, 7, 474-483.	3.5	5
525	Antihypertensive, antiproteinuric therapy and myocardial infarction and stroke prevention. <i>Current Hypertension Reports</i> , 2005, 7, 367-373.	3.5	4
526	BENEDICT in the treatment of hypertension. <i>Current Hypertension Reports</i> , 2005, 7, 121-123.	3.5	5
527	Prevention of Nephropathy in Patients with type 2 Diabetes Mellitus. <i>International Urology and Nephrology</i> , 2005, 37, 655-663.	1.4	8

#	ARTICLE	IF	CITATIONS
528	GPs' perspectives of type 2 diabetes patients' adherence to treatment: A qualitative analysis of barriers and solutions. <i>BMC Family Practice</i> , 2005, 6, 20.	2.9	137
529	Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 795-803.	1.9	75
530	ACE Inhibitor Trials: Effects in Hypertension. , 2005, , 386-390.		0
531	Predictors of Health Care Costs in Adults With Diabetes. <i>Diabetes Care</i> , 2005, 28, 59-64.	8.6	193
533	The Diabetic RETinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005, 6, 25-32.	1.7	59
534	Has Control of Hypercholesterolemia and Hypertension in Type 1 Diabetes Improved Over Time?. <i>Diabetes Care</i> , 2005, 28, 521-526.	8.6	38
535	Effective management of type 2 diabetes and metabolic syndrome: beyond glucose control. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 303-304.	0.6	0
536	Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. <i>Heart</i> , 2005, 91, 451-455.	2.9	14
537	Hypertension in type 2 diabetes - targeting angiotensin. <i>Drug and Therapeutics Bulletin</i> , 2005, 43, 41-45.	0.3	1
538	Antihypertensive Agents for Primary Prevention of Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3081-3091.	6.1	74
539	Hypertension 2005: an evidence-based approach to diagnosis and treatment – an American perspective. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 691-704.	1.5	5
540	Specialist Nurse-Led Clinics to Improve Control of Hypertension and Hyperlipidemia in Diabetes: Economic analysis of the SPLINT trial. <i>Diabetes Care</i> , 2005, 28, 40-46.	8.6	59
541	Pro-Active Call Center Treatment Support (PACCTS) to Improve Glucose Control in Type 2 Diabetes: A randomized controlled trial. <i>Diabetes Care</i> , 2005, 28, 278-282.	8.6	93
542	Determinants of Diabetes-Attributable Non-Blood Glucose-Lowering Medication Costs in Type 2 Diabetes: The Fremantle Diabetes Study. <i>Diabetes Care</i> , 2005, 28, 329-336.	8.6	27
543	Current and future pharmacological intervention for diabetic retinopathy. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 441-455.	2.4	16
544	Hypertension-based clinical risk strategies for detecting microalbuminuria in diabetes. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 427-433.	0.5	3
545	The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. <i>European Heart Journal</i> , 2005, 26, 1369-1378.	2.2	127
546	Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. <i>Lancet</i> , The, 2005, 366, 1545-1553.	13.7	942

#	ARTICLE	IF	CITATIONS
550	Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). <i>Diabetes and Metabolism</i> , 2005, 31, 479-485.	2.9	29
552	Integrated Management of Patients with Diabetes Mellitus and Ischemic Heart Disease: PCI, CABG, and Medical Therapy. <i>Current Problems in Cardiology</i> , 2005, 30, 583-617.	2.4	4
553	Strategies to Retard the Progression of Chronic Kidney Disease. <i>Medical Clinics of North America</i> , 2005, 89, 489-509.	2.5	25
555	Therapeutic Controversies in Hypertension. <i>Seminars in Nephrology</i> , 2005, 25, 227-235.	1.6	7
556	Évaluation de l'impact budgétaire de l'application des recommandations de bonne pratique dans le diabète de type II en France. <i>Revue D'Epidemiologie Et De Sante Publique</i> , 2005, 53, 67-78.	0.5	6
557	Hypertension and the Kidney. <i>Seminars in Nephrology</i> , 2005, 25, 236-245.	1.6	22
558	Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. <i>Cardiology Clinics</i> , 2005, 23, 139-152.	2.2	33
559	Drug-induced diabetes mellitus. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 1097-1109.	2.4	34
560	Carvedilol: New Considerations for Its Use in the Diabetic Patient With Hypertension. <i>Journal of Clinical Hypertension</i> , 2005, 7, 59-64.	2.0	5
561	Early Initiation of β Blockade in Heart Failure: Issues and Evidence. <i>Journal of Clinical Hypertension</i> , 2005, 7, 520-528.	2.0	10
562	Treatment of Diabetic Hypertensive Patients: Results of a National Survey. <i>Journal of Clinical Hypertension</i> , 2005, 7, 110-110.	2.0	0
563	Cardioprotection: The Role of β -Blocker Therapy. <i>Journal of Clinical Hypertension</i> , 2005, 7, 409-416.	2.0	34
565	Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention Trials. <i>Hypertension Research</i> , 2005, 28, 385-407.	2.7	229
566	Grado de control de la presión arterial en un grupo de pacientes con diabetes mellitus tipo 2. <i>Endocrinología Y Nutrición: Organo De La Sociedad Espanola De Endocrinología Y Nutrición</i> , 2005, 52, 493-497.	0.8	0
567	Néphropathie diabétique et traitement antihypertenseur: quelles sont les leçons des essais cliniques?. <i>EMC - Nephrologie</i> , 2005, 2, 182-193.	0.0	0
569	Hypertension Management in Type 2 Diabetes Mellitus: Recommendations of the Joint National Committee VII. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 63-75.	3.2	22
570	Stroke prevention in diabetes and obesity. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 487-502.	1.5	20
571	Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus. <i>Pharmacoeconomics</i> , 2006, 24, 425-441.	3.3	42

#	ARTICLE	IF	CITATIONS
572	Metabolic Effects of β -Adrenoceptor Antagonists with Special Emphasis on Carvedilol. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 209-217.	2.2	36
573	Prevention of Cardiovascular Complications of the Metabolic Syndrome: Focus on Pharmacotherapy. <i>Metabolic Syndrome and Related Disorders</i> , 2006, 4, 328-341.	1.3	4
574	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2006, 37, 577-617.	2.0	1,510
575	Characteristics and six-month outcomes in a cohort of 8288 diabetic and non-diabetic patients with previous history of acute coronary syndrome or stroke: the French PREVENIR 3 survey. <i>Diabetes and Metabolism</i> , 2006, 32, 460-466.	2.9	9
577	β blockers for the treatment of primary hypertension. <i>Lancet</i> , The, 2006, 367, 209.	13.7	8
578	New guidelines on hypertension. <i>Lancet</i> , The, 2006, 368, 641.	13.7	6
580	Type-2 diabetes mellitus related cardiovascular risk: New options for interventions to reduce risk and treatment goals. <i>Atherosclerosis Supplements</i> , 2006, 7, 29-32.	1.2	63
581	Diabetic Hypertension. <i>Heart Failure Clinics</i> , 2006, 2, 25-36.	2.1	4
582	Manitoba Diabetes Care Project: A1C and Microalbumin Testing. <i>Canadian Journal of Diabetes</i> , 2006, 30, 1-7.	0.8	2
583	Blood Pressure Lowering for the Prevention and Treatment of Diabetic Kidney Disease. <i>Drugs</i> , 2006, 66, 2213-2234.	10.9	36
584	Diabetic Cardiomyopathy. <i>Heart Failure Clinics</i> , 2006, 2, 71-80.	2.1	2
585	Section 3: Prevention of Ventricular Remodeling, Cardiac Dysfunction, and Heart Failure. <i>Journal of Cardiac Failure</i> , 2006, 12, e12-e15.	1.7	1
586	Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. <i>Journal of Cardiac Failure</i> , 2006, 12, 10-38.	1.7	491
587	Angiotensin and diabetic retinopathy. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 752-765.	2.8	136
588	Do the Metabolic Effects of β Blockers Make Them Leading or Supporting Antihypertensive Agents in the Treatment of Hypertension?. <i>Journal of Clinical Hypertension</i> , 2006, 8, 351-356.	2.0	21
589	Challenges and Risks in Attaining the Systolic Blood Pressure Goal of <130 mm Hg in All Diabetic Patients. <i>Journal of Clinical Hypertension</i> , 2006, 8, 50-52.	2.0	1
590	Hypertension—A Treatable Component of the Cardiometabolic Syndrome: Challenges for the Primary Care Physician. <i>Journal of Clinical Hypertension</i> , 2006, 8, 12-20.	2.0	7
591	Review Paper $\frac{1}{2}$ CME. Insulin Resistance, Diabetes, Hypertension, and Renin-Angiotensin System Inhibition: Reducing Risk for Cardiovascular Disease. <i>Journal of Clinical Hypertension</i> , 2006, 8, 713-722.	2.0	35

#	ARTICLE	IF	CITATIONS
592	Antihypertensive Prescribing Practices: Impact of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Journal of Clinical Hypertension</i> , 2006, 8, 860-864.	2.0	13
593	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2006, 113, .	1.6	416
594	Revisiting the metabolic syndrome. <i>Medical Journal of Australia</i> , 2006, 185, 445-449.	1.7	67
596	Cardiovascular Disease. <i>Journal of Cardiovascular Nursing</i> , 2006, 21, S20-S42.	1.1	7
598	How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2006, 24, 2131-2141.	0.5	138
599	Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. <i>Journal of Hypertension</i> , 2006, 24, 11-25.	0.5	101
600	Update on Hypertension Management: Treatment of hypertension in patients with type 2 diabetes mellitus. <i>Journal of Hypertension</i> , 2006, 24, 208-210.	0.5	8
601	Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. <i>Journal of Hypertension</i> , 2006, 24, 185-192.	0.5	47
602	Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. <i>Journal of Hypertension</i> , 2006, 24, 1397-1403.	0.5	73
603	Anti-diabetic effect of blockade of the renin-angiotensin system. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 396-403.	4.4	26
604	Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 295-309.	46.4	230
605	Japanese Society of Hypertension. <i>Hypertension Research</i> , 2006, 29, S1-S105.	2.7	32
606	Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension. <i>Journal of Human Hypertension</i> , 2006, 20, 599-611.	2.2	19
607	Beta-receptor blockers in primary prevention for cardiovascular disease: forgotten benefits?. <i>Journal of Human Hypertension</i> , 2006, 20, 719-721.	2.2	3
608	Influence of antihypertensive therapy and blood pressure control on left ventricular geometry and function in subjects with type II diabetes: The Augsburg Diabetes Family Study. <i>Journal of Human Hypertension</i> , 2006, 20, 757-764.	2.2	4
609	ACE-inhibitor use and the long-term risk of renal failure in diabetes. <i>Kidney International</i> , 2006, 69, 913-919.	5.2	117
610	Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. <i>Kidney International</i> , 2006, 69, 2057-2063.	5.2	414
611	Decrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats. <i>Kidney International</i> , 2006, 70, 471-476.	5.2	33

#	ARTICLE	IF	CITATIONS
612	Beta blockers in the management of chronic kidney disease. <i>Kidney International</i> , 2006, 70, 1905-1913.	5.2	164
613	Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 295-308.	2.6	25
614	Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). <i>Diabetologia</i> , 2006, 49, 1761-1769.	6.3	303
617	Modifications of Coronary Risk Factors. <i>American Journal of Cardiology</i> , 2006, 97, 41-52.	1.6	17
618	From JNC I to JNC 7â€”What Have We Learned?. <i>Progress in Cardiovascular Diseases</i> , 2006, 48, 303-315.	3.1	26
619	Long-term safety of antihypertensive therapy. <i>Progress in Cardiovascular Diseases</i> , 2006, 49, 16-25.	3.1	25
620	Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J). <i>BMC Cardiovascular Disorders</i> , 2006, 6, 39.	1.7	5
621	Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall. <i>BMC Health Services Research</i> , 2006, 6, 47.	2.2	17
622	Carvedilol versus Cardioselective Î²-Blockers for the Treatment of Hypertension in Patients with Type 2 Diabetes Mellitus. <i>Pharmacotherapy</i> , 2006, 26, 1491-1500.	2.6	8
623	Coronary Artery Disease and Hypertension: Outcomes of a Pharmacist-Managed Blood Pressure Program. <i>Pharmacotherapy</i> , 2006, 26, 1333-1341.	2.6	23
624	Renoprotection by blocking the RAAS in diabetic nephropathyâ€”fact or fiction?. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2354-2357.	0.7	25
625	Nebivolol: novel Î²-blocker with nitric oxide-induced vasodilation. <i>Future Cardiology</i> , 2006, 2, 9-16.	1.2	2
626	Re-examining the efficacy of Å-blockers for the treatment of hypertension: a meta-analysis. <i>Cmaj</i> , 2006, 174, 1737-1742.	2.0	179
628	Therapeutic potential of angiotensin receptor blockers in hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 625-635.	4.1	6
629	Pitfalls in blood pressure measurement in daily practice. <i>Family Practice</i> , 2006, 23, 20-27.	1.9	22
630	Clinical Decision-Making in Blood Pressure Management of Patients with Diabetes Mellitus: An Oklahoma Physicians Resource/Research Network (OKPRN) Study. <i>Journal of the American Board of Family Medicine</i> , 2006, 19, 232-239.	1.5	16
632	Developing a Church-Based Diabetes Prevention Program With African Americans. <i>The Diabetes Educator</i> , 2006, 32, 901-909.	2.5	42
633	The Metabolic Syndrome Is a Risk Indicator of Microvascular and Macrovascular Complications in Diabetes. <i>Diabetes Care</i> , 2006, 29, 2701-2707.	8.6	174

#	ARTICLE	IF	CITATIONS
634	Risk Factors for Renal Dysfunction in Type 2 Diabetes. <i>Diabetes</i> , 2006, 55, 1832-1839.	0.6	815
635	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. <i>Circulation</i> , 2006, 114, 2850-2870.	1.6	346
636	Blood pressure control and prevention of stroke. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 203-212.	2.8	0
637	The Pharmacist's Role in Continuity of Care in Type 2 Diabetes: An Evaluation of a Model. <i>Journal of Pharmacy Technology</i> , 2006, 22, 3-8.	1.0	10
638	Inhalation of Human Insulin (Exubera) Augments the Efficiency of Muscle Glucose Uptake In Vivo. <i>Diabetes</i> , 2006, 55, 3604-3610.	0.6	11
639	Blood Pressure Reduction Is Not the Only Determinant of Outcome. <i>Circulation</i> , 2006, 113, 2754-2774.	1.6	66
640	Progression of Renal Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1054-1065.	4.5	86
641	Impact of Office Systems and Improvement Strategies on Costs of Care for Adults With Diabetes. <i>Diabetes Care</i> , 2006, 29, 1242-1248.	8.6	20
642	Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients. <i>The American Journal of Geriatric Cardiology</i> , 2007, 16, 24-29.	0.6	11
643	Diabetes, the Metabolic Syndrome, and Ischemic Stroke. <i>Diabetes Care</i> , 2007, 30, 3131-3140.	8.6	140
645	Blood pressure, antihypertensive treatment and factors associated with good blood pressure control in hypertensive diabetics: the Tarmidas study. <i>Journal of Human Hypertension</i> , 2007, 21, 664-672.	2.2	10
646	Use of Chronic Care Model Elements Is Associated With Higher-Quality Care for Diabetes. <i>Annals of Family Medicine</i> , 2007, 5, 14-20.	1.9	143
647	Effect of Periodontitis on Overt Nephropathy and End-Stage Renal Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 306-311.	8.6	253
648	Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. <i>Journal of Hypertension</i> , 2007, 25, 951-958.	0.5	372
649	Endocrine Disorders and the Heart. , 2007, , 2295-2330.		1
650	Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study. <i>Hypertension</i> , 2007, 50, 299-305.	2.7	174
651	Beta-blockers for hypertension. , 2007, , CD002003.		126
652	Metabolic Syndrome: Treatment of Hypertensive Patients. <i>American Journal of Therapeutics</i> , 2007, 14, 386-402.	0.9	40

#	ARTICLE	IF	CITATIONS
653	Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke?. Journal of Hypertension, 2007, 25, 1543-1553.	0.5	35
654	Diabetic Nephropathy and Pregnancy. Clinical Obstetrics and Gynecology, 2007, 50, 998-1006.	1.1	91
656	Use of β_2 -blockers and β_2 -agonists in COPD: A review of clinical outcomes. Respiratory Medicine: COPD Update, 2007, 2, 133-139.	0.0	3
657	A Modern Perspective on β -Blocker Use in Hypertension: Clinical Trials and Their Influence on Clinical Practice. Journal of Clinical Hypertension, 2007, 9, 10-18.	2.0	10
658	Direct Renin Inhibitors: A New Approach to Antihypertensive Drug Treatment. Journal of Clinical Hypertension, 2007, 9, 615-621.	2.0	2
659	ACE Inhibitors and ARBs: Are They Better Than Other Agents to Slow Nephropathy Progression?. Journal of Clinical Hypertension, 2007, 9, 413-415.	2.0	4
660	Hypertension Treatment Guidelines: Is It Time for an Update?. Journal of Clinical Hypertension, 2007, 9, 9-14.	2.0	9
661	Body Weight Changes with β_2 -Blocker Use: Results from GEMINI. American Journal of Medicine, 2007, 120, 610-615.	1.5	95
662	Effects of angiotensin-converting enzyme inhibitors and β_2 -adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Experimental Eye Research, 2007, 84, 745-752.	2.6	34
663	Clinical practice and guidelines in Europe for the treatment of hypertension, with a focus on patients with diabetes mellitus. Clinical Therapeutics, 2007, 29, S44-S53.	2.5	2
664	A simple nurse-based prompt increases screening and prevention counseling for diabetes. Diabetes Research and Clinical Practice, 2007, 75, 81-87.	2.8	10
665	Sight-threatening retinopathy is associated with lower mortality in type 2 diabetic subjects: A 10-year observation study. Diabetes Research and Clinical Practice, 2007, 77, 141-147.	2.8	16
667	Are we misunderstanding beta-blockers. International Journal of Cardiology, 2007, 120, 10-27.	1.7	86
669	Traitement mÃ©dicamenteux du diabÃ©te de type 2recommandation de bonne pratique. Diabetes and Metabolism, 2007, 33, S26-S105.	2.9	5
670	2007 ESHÃ©ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2007, 16, 135-232.	1.5	292
671	Progress Report on the Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) Study: Status at February 2004. Clinical and Experimental Hypertension, 2007, 29, 69-81.	1.3	10
672	Therapeutic interventions for hypertension in metabolic syndrome: a comprehensive approach. Expert Review of Cardiovascular Therapy, 2007, 5, 201-211.	1.5	4
673	Effects of Antihypertensives on Glucose Metabolism. Metabolic Syndrome and Related Disorders, 2007, 5, 211-219.	1.3	19

#	ARTICLE	IF	CITATIONS
674	Necesidades de mejora y limitaciones en el tratamiento de la diabetes mellitus. Perspectiva del endocrinólogo. <i>Pharmacoeconomics - Spanish Research Articles</i> , 2007, 4, 25-31.	0.0	0
675	Global management of high risk patients: Integrated primary cardiovascular prevention in diabetics. <i>International Congress Series</i> , 2007, 1303, 10-20.	0.2	2
676	Applying Hypertension Guidelines to Reduce the Burden of Heart Failure. <i>Cardiology Clinics</i> , 2007, 25, 507-522.	2.2	6
677	Should β -Blockers Be Used to Control Hypertension in People With Chronic Kidney Disease?. <i>Seminars in Nephrology</i> , 2007, 27, 555-564.	1.6	32
680	Imidapril. <i>Drugs</i> , 2007, 67, 1379-1382.	10.9	2
681	The Role of Sulodexide in the Treatment of Diabetic Nephropathy. <i>Drugs</i> , 2007, 67, 2681-2696.	10.9	41
682	Management of hypertension in diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 341-357.	2.4	0
684	Pathophysiology of Obesity-Induced Hypertension and Target Organ Damage. , 2007, , 447-468.		13
685	Blockade of the renin-angiotensin system for renal future perspectives protection: from history to future perspective. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007, 8, 208-211.	1.7	1
686	Control of Blood Glucose and Insulin Resistance. , 2007, , 1105-1112.		1
687	Preventing microalbuminuria in patients with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 100-110.	4.0	18
688	The Ontario printed educational message (OPEM) trial to narrow the evidence-practice gap with respect to prescribing practices of general and family physicians: a cluster randomized controlled trial, targeting the care of individuals with diabetes and hypertension in Ontario, Canada. <i>Implementation Science</i> , 2007, 2, 37.	6.9	18
689	Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 412-421.	1.9	27
690	Blood pressure control in type II diabetics with diabetic retinopathy. <i>Eye</i> , 2007, 21, 708-711.	2.1	15
691	CHRONIC SALT LOADING AND CARDIOVASCULAR-ASSOCIATED CHANGES IN EXPERIMENTAL DIABETES IN RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 574-580.	1.9	5
692	β -Blocker use and diabetes symptom score: results from the GEMINI study. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 408-417.	4.4	27
693	The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. <i>Diabetic Medicine</i> , 2007, 24, 677-683.	2.3	154
694	Discordant Effects of β -Blockade on Central Aortic Systolic and Brachial Systolic Blood Pressure: Considerations Beyond the Cuff. <i>Pharmacotherapy</i> , 2007, 27, 1322-1333.	2.6	10

#	ARTICLE	IF	CITATIONS
695	Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S44-S55.	1.6	125
696	Angiotensin Receptor Blockers versus Angiotensin-Converting Enzyme Inhibitors: Where Do We Stand Now?. <i>American Journal of Cardiology</i> , 2007, 100, S38-S44.	1.6	39
697	Antihypertensive Therapy in the Presence of Proteinuria. <i>American Journal of Kidney Diseases</i> , 2007, 49, 12-26.	1.9	671
701	Hypertension in people with diabetes and the metabolic syndrome: Pathophysiologic insights and therapeutic update. <i>Current Diabetes Reports</i> , 2007, 7, 208-217.	4.2	13
702	Beta-blocker contraindications: Are there patients or situations where use is inappropriate?. <i>Current Heart Failure Reports</i> , 2007, 4, 93-98.	3.3	1
703	Beta-blockers to prevent symptomatic heart failure in patients with stage A and B heart failure. <i>Current Heart Failure Reports</i> , 2007, 4, 99-102.	3.3	4
704	ADVANCE in management of vascular complications of diabetes. <i>Current Hypertension Reports</i> , 2008, 10, 255-257.	3.5	0
705	RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. <i>Clinical Research in Cardiology</i> , 2008, 97, 418-431.	3.3	135
706	Hypertension management in diabetic patients: prescribing trends from 1999 to 2005 in three Japanese university hospitals. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 904-911.	1.9	10
707	Beta-blockers should remain as first-line therapy in the management of hypertension. <i>International Journal of Clinical Practice</i> , 2008, 62, 1137-1141.	1.7	2
708	Retinal ganglion cells in diabetes. <i>Journal of Physiology</i> , 2008, 586, 4401-4408.	2.9	341
709	Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 533-544.	4.4	8
710	Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?. <i>Diabetic Medicine</i> , 2008, 25, 25-29.	2.3	143
711	The Hypertension in Diabetes Study (HDS): a catalyst for change. <i>Diabetic Medicine</i> , 2008, 25, 13-19.	2.3	14
712	Use of Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy to Reduce Cardiovascular Events in High-Risk Patients: Part 1. <i>Preventive Cardiology</i> , 2008, 11, 148-154.	1.1	7
713	Association between diabetes patients' knowledge about medications and their blood glucose control. <i>Research in Social and Administrative Pharmacy</i> , 2008, 4, 37-45.	3.0	84
714	The Metabolic Syndrome. <i>Endocrine Reviews</i> , 2008, 29, 777-822.	20.1	1,513
715	Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus. <i>Medicina Clínica</i> , 2008, 130, 641-644.	0.6	13

#	ARTICLE	IF	CITATIONS
716	10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 1577-1589.	27.0	6,543
717	Retinopatía diabética y ceguera en España. <i>Epidemiología y prevención</i> . <i>Endocrinología Y Nutricion: Organó De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2008, 55, 459-475.	0.8	9
718	Beta-Blocker Therapy in Hypertension: A Need to Pause and Reflect. <i>Journal of the American College of Cardiology</i> , 2008, 51, 516-517.	2.8	2
719	Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1062-1072.	2.8	90
720	Renin-angiotensin system blockade in diabetic nephropathy. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2008, 2, 135-158.	3.6	4
721	Microvascular and Macrovascular Complications of Diabetes. <i>Clinical Diabetes</i> , 2008, 26, 77-82.	2.2	1,365
722	Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. <i>Nutrition Research</i> , 2008, 28, 315-320.	2.9	95
723	Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. <i>Diabetes and Metabolism</i> , 2008, 34, 560-567.	2.9	85
724	Mutations in the $\beta 1$ adrenergic receptor gene and massive obesity in Japanese. <i>Diabetes Research and Clinical Practice</i> , 2008, 80, 213-217.	2.8	3
725	Does it matter how blood pressure is lowered in patients with metabolic risk factors?. <i>Journal of the American Society of Hypertension</i> , 2008, 2, S23-S29.	2.3	7
726	Tratamiento de la hipertensión en los pacientes diabéticos. <i>Clínica E Investigación En Arteriosclerosis</i> , 2008, 20, 253-258.	0.8	1
727	Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. <i>Canadian Journal of Cardiology</i> , 2008, 24, 491-496.	1.7	50
728	Nefroprotección. Bloqueo del sistema renina-angiotensina. <i>Semergen</i> , 2008, 34, 127-132.	0.5	0
729	Caring for the Vulnerable Elderly: Are Available Quality Indicators Appropriate?. <i>Journal of the American Medical Directors Association</i> , 2008, 9, 1-3.	2.5	23
730	High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins. <i>Annals of Medicine</i> , 2008, 40, 209-214.	3.8	13
731	Review: α -blockers for hypertension increase risk of new onset diabetes. <i>Evidence-Based Medicine</i> , 2008, 13, 50-50.	0.6	14
732	Management of Hypertension in Diabetic Patients With Chronic Kidney Disease. <i>Diabetes Spectrum</i> , 2008, 21, 30-36.	1.0	12
733	Is Relative Mortality of Type 2 Diabetes Mellitus Decreasing?. <i>American Journal of Epidemiology</i> , 2008, 169, 455-461.	3.4	59

#	ARTICLE	IF	CITATIONS
734	Diabetes, left ventricular systolic dysfunction, and chronic heart failure. <i>European Heart Journal</i> , 2008, 29, 1224-1240.	2.2	184
735	Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. <i>European Heart Journal</i> , 2008, 29, 2669-2680.	2.2	225
736	Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 289-303.	1.5	11
737	Prevalence of Albuminuria and Cardiovascular Risk Profile in a Referred Cohort of Patients with Type 2 Diabetes: An Asian Perspective. <i>Diabetes Technology and Therapeutics</i> , 2008, 10, 397-403.	4.4	27
738	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 1565-1576.	27.0	674
739	Implications of ethnicity for the treatment of hypertensive kidney disease, with an emphasis on African Americans. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 538-549.	2.0	19
740	Sex Disparities in Control and Treatment of Modifiable Cardiovascular Disease Risk Factors Among Patients With Diabetes. <i>Diabetes Care</i> , 2008, 31, 69-74.	8.6	149
741	Preventing diabetic retinopathy through control of systemic factors. , 2008, , 203-219.		0
742	Treating Elderly People with Diabetes and Stages 3 and 4 Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1185-1194.	4.5	39
743	Management of Coronary Artery Disease in Type 2 Diabetes Mellitus. , 2008, , 289-319.		1
744	An Appreciation of Robert Turner. <i>Diabetes</i> , 2008, 57, 2918-2921.	0.6	2
745	Prevention of Heart Failure. <i>Circulation</i> , 2008, 117, 2544-2565.	1.6	485
746	In Half of Hypertensive Diabetics, Co-Administration of a Calcium Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor Achieved a Target Blood Pressure of $\leq 130/80\text{mmHg}$: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes (ATTEST) Study. <i>Hypertension Research</i> , 2008, 31, 1499-1508.	2.7	11
747	Continuing evolution of the role of β -blockers in the treatment of hypertension. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 773-778.	0.2	1
748	Choice of antihypertensive drugs in the European Society of Hypertensionâ€“European Society of Cardiology guidelines: specific indications rather than ranking for general usage. <i>Journal of Hypertension</i> , 2008, 26, 164-168.	0.5	30
749	Beta-blockade should not be among several choices for initial therapy of hypertension. <i>Journal of Hypertension</i> , 2008, 26, 161-163.	0.5	11
750	Secondary Stroke Prevention. <i>Journal of Cardiovascular Nursing</i> , 2008, 23, 34-41.	1.1	22
751	Management of increased cardiovascular risk. , 0, , 148-174.		0

#	ARTICLE	IF	CITATIONS
753	Hypertension and Diabetes: Critical Comorbidities. <i>Journal for Vascular Ultrasound</i> , 2008, 32, 17-20.	0.1	0
754	DIABETES MELLITUS: OLD ASSUMPTIONS AND NEW REALITIES. , 2008, , 23-32.		0
755	Estudo comparativo da evolu��o e sobrevida de pacientes com claudica��o intermitente, com ou sem limita��o para exerc�cios, acompanhados em ambulat�rio espec�fico. <i>Jornal Vascular Brasileiro</i> , 2008, 7, 112-122.	0.5	8
756	Management of type 2 diabetes mellitus in Greenland, 2008: examining the quality and organization of diabetes care. <i>International Journal of Circumpolar Health</i> , 2009, 68, 123-132.	1.2	9
757	Rosiglitazone in Canada: experience in clinical practice. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 441-448.	3.3	1
758	Treatment of Mild to Moderate Hypertension by Gender Perspective: A Systematic Review. <i>Journal of Women's Health</i> , 2009, 18, 1049-1062.	3.3	16
759	Rho Kinase Inhibition by Fasudil Ameliorates Diabetes-Induced Microvascular Damage. <i>Diabetes</i> , 2009, 58, 215-226.	0.6	188
760	Effect of Metformin on Weight Gain During Antihypertensive Treatment With a �-Blocker in Chinese Patients. <i>American Journal of Hypertension</i> , 2009, 22, 884-890.	2.0	5
761	Perioperative Blood Glucose Monitoring in the General Surgical Population. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 1282-1287.	2.2	22
762	A role for single-pill triple therapy in hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2009, 3, 231-240.	2.1	22
763	Advances in the Medical Treatment of Diabetic Retinopathy. <i>Diabetes Care</i> , 2009, 32, 1556-1562.	8.6	124
764	Effect of Diabetes Medications on Cardiovascular Risk and Surrogate Markers in Patients with Type 2 Diabetes. <i>Journal of Pharmacy Technology</i> , 2009, 25, 24-36.	1.0	0
765	Recent clinical trials in diabetes �� implications for managing older patients. <i>Reviews in Clinical Gerontology</i> , 2009, 19, 25-33.	0.5	0
766	(Pro)renin Receptor��Mediated Signal Transduction and Tissue Renin-Angiotensin System Contribute to Diabetes-Induced Retinal Inflammation. <i>Diabetes</i> , 2009, 58, 1625-1633.	0.6	136
767	A Summary of the ADVANCE Trial. <i>Diabetes Care</i> , 2009, 32, S357-S361.	8.6	88
768	Follow-up of Intensive Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2009, 360, 416-418.	27.0	12
769	Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 689-702.	1.5	28
770	Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial. <i>Hypertension Research</i> , 2009, 32, 248-254.	2.7	29

#	ARTICLE	IF	CITATIONS
771	Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?. <i>Journal of the American Board of Family Medicine</i> , 2009, 22, 686-697.	1.5	20
772	Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead. <i>Journal of Clinical Hypertension</i> , 2009, 11, 636-643.	2.0	30
773	Kallidinogenase normalizes retinal vasopermeability in streptozotocin-induced diabetic rats: Potential roles of vascular endothelial growth factor and nitric oxide. <i>European Journal of Pharmacology</i> , 2009, 606, 187-190.	3.5	14
774	The Kidney Disease Initiative and the Division of Diabetes Translation at the Centers for Disease Control and Prevention. <i>American Journal of Kidney Diseases</i> , 2009, 53, S121-S125.	1.9	16
775	Evidence-based Practice Guideline for the Treatment of CKD. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 537-566.	1.6	106
776	An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care. <i>Irish Journal of Medical Science</i> , 2009, 178, 179-186.	1.5	14
777	Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials. <i>Current Diabetes Reports</i> , 2009, 9, 229-237.	4.2	10
778	Pharmacologic management of patients with both heart failure and diabetes. <i>Current Heart Failure Reports</i> , 2009, 6, 126-132.	3.3	3
779	Update on the metabolic syndrome: Hypertension. <i>Current Hypertension Reports</i> , 2009, 11, 150-155.	3.5	18
780	Choosing the ideal drug for hypertension after ischemic stroke. <i>Current Hypertension Reports</i> , 2009, 11, 246-252.	3.5	2
782	Barriers and facilitators to evidence based care of type 2 diabetes patients: experiences of general practitioners participating to a quality improvement program. <i>Implementation Science</i> , 2009, 4, 41.	6.9	42
783	Effect of systemic administration of valsartan, an angiotensin II type 1 receptor blocker, on retinal circulation in healthy humans. <i>Eye</i> , 2009, 23, 1491-1992.	2.1	3
784	Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 140-148.	1.4	40
785	Dr Fisher's Casebook. <i>Significance</i> , 2009, 6, 76-77.	0.4	0
786	Short report: suboptimal diabetes care in high-risk diabetic patients attending a specialist retina clinic. <i>Diabetic Medicine</i> , 2009, 26, 1296-1300.	2.3	5
787	The sweeter side of ACE2: Physiological evidence for a role in diabetes. <i>Molecular and Cellular Endocrinology</i> , 2009, 302, 193-202.	3.2	183
788	Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers. <i>American Heart Journal</i> , 2009, 157, 334.e1-334.e8.	2.7	25
790	Blocking the renin-angiotensin system: dual- versus mono-therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 667-674.	1.5	16

#	ARTICLE	IF	CITATIONS
791	Beta-Blockers and Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2105-2106.	2.8	1
792	First-line drugs for hypertension. <i>The Cochrane Library</i> , 2009, , CD001841.	2.8	130
793	Stroke and Diabetes Mellitus. , 2009, , 183-218.		1
794	Role of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Hypertension in Patients Aged ≥65 Years. <i>Drugs and Aging</i> , 2009, 26, 751-767.	2.7	15
795	Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1285-1303.	3.3	5
796	Blood Pressure-Lowering Effects of Angiotensin Receptor Antagonist Monotherapy and in Combination with Other Anti-Hypertensive Drugs in Primary Care Settings in Japan. <i>Clinical and Experimental Hypertension</i> , 2009, 31, 127-141.	1.3	5
797	A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 149-162.	2.2	8
798	Appropriate, timely, and rational treatment of type 2 diabetes mellitus: Meeting the challenges of primary care. <i>Insulin</i> , 2009, 4, 144-157.	0.2	4
799	Macrovascular Complications of Diabetes Mellitus. <i>Journal of Pharmacy Practice</i> , 2009, 22, 135-148.	1.0	10
800	Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. <i>Cardiovascular Therapeutics</i> , 2009, 27, 199-215.	2.5	10
801	Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. <i>Journal of Neurology</i> , 2009, 256, 1603-1619.	3.6	47
802	The Kidney, Hypertension, and Remaining Challenges. <i>Medical Clinics of North America</i> , 2009, 93, 697-715.	2.5	43
803	Diabetic Nephropathy in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 373-389.	2.6	10
804	Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus. <i>Gender Medicine</i> , 2009, 6, 86-108.	1.4	36
805	Evidence for a lower target blood pressure for people with heart disease. <i>Current Opinion in Cardiology</i> , 2009, 24, 318-324.	1.8	12
806	An Algorithm for the Care of Type 2 Diabetes. <i>Critical Pathways in Cardiology</i> , 2009, 8, 156-165.	0.5	4
807	Comparative Analysis of Beta-Blockers With Other Antihypertensive Agents on Cardiovascular Outcomes in Hypertensive Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>American Journal of Therapeutics</i> , 2009, 16, 133-142.	0.9	21
808	Incidence of New Stroke or New Myocardial Infarction or Death at 39-Month Follow Up in Patients With Diabetes Mellitus, Hypertension, or Both Treated With and Without Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. <i>American Journal of Therapeutics</i> , 2009, 16, 2-4.	0.9	5

#	ARTICLE	IF	CITATIONS
809	Linking diabetes and atherosclerosis. Expert Review of Endocrinology and Metabolism, 2009, 4, 603-624.	2.4	8
810	Prevention of risk factors: beta-blockade and hypertension. European Heart Journal Supplements, 2009, 11, A3-A8.	0.1	8
811	The Myth of Janus. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 35-37.	2.2	0
812	Crucial role of kidney function in resistance to antihypertensive therapy in patients with diabetes mellitus. Journal of Hypertension, 2010, 28, 2323-2328.	0.5	11
813	Early Age-Related Macular Degeneration Impairs Tolerance to Stimulus Degradation. Optometry and Vision Science, 2010, 87, 532-542.	1.2	7
814	Finding a niche with personalized generics: opportunities from systems-based therapeutic delivery in hypertension. Therapeutic Delivery, 2010, 1, 683-691.	2.2	1
818	Evidence for Aggressive Blood Pressure“Lowering Goals in Patients with Coronary Artery Disease. Current Atherosclerosis Reports, 2010, 12, 134-139.	4.8	10
819	Best Strategies for Hypertension Management in Type 2 Diabetes and Obesity. Current Diabetes Reports, 2010, 10, 139-144.	4.2	25
820	Rationale and design of the NAGOYA HEART Study: Comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology, 2010, 56, 111-117.	1.9	13
821	The renin“angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Progress in Retinal and Eye Research, 2010, 29, 284-311.	15.5	123
822	From design to implementation - The Joint Asia Diabetes Evaluation (JADE) program: A descriptive report of an electronic web-based diabetes management program. BMC Medical Informatics and Decision Making, 2010, 10, 26.	3.0	46
823	Is There Accord in ACCORD? Lower Blood Pressure Targets in Type 2 Diabetes Does Not Lead to Fewer Cardiovascular Events Except for Reductions in Stroke. Journal of Clinical Hypertension, 2010, 12, 472-477.	2.0	5
825	Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization. Cardiovascular Diabetology, 2010, 9, 1.	6.8	38
826	Diabetes and obesity: therapeutic targeting and risk reduction “ a complex interplay. Diabetes, Obesity and Metabolism, 2010, 12, 267-287.	4.4	76
827	Prevention and management of chronic kidney disease in type 2 diabetes. Nephrology, 2010, 15, S162-94.	1.6	17
828	Cost“effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes. Nephrology, 2010, 15, S195-203.	1.6	8
829	Hypertensive Kidney Disease. , 2010, , 57-67.		0
830	Diabetic Retinopathy. Deutsches Ärzteblatt International, 2010, 107, 75-83; quiz 84.	0.9	137

#	ARTICLE	IF	CITATIONS
831	Improving Blood Pressure Control in Patients with Diabetes Mellitus and High Cardiovascular Risk. International Journal of Hypertension, 2010, 2010, 1-8.	1.3	7
832	Lacunar Strokes and Hypertensive Encephalopathy. , 0, , 135-142.		0
833	Management of High Blood Pressure in Blacks. Hypertension, 2010, 56, 780-800.	2.7	398
834	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2010, 362, 1575-1585.	27.0	3,117
835	Approach to Managing Hypoglycemia in Elderly Patients with Diabetes. Postgraduate Medicine, 2010, 122, 129-137.	2.0	51
836	Vascular damage in diabetic retinopathy. , 2010, , 506-513.		3
837	Systemic Side Effects of Glaucoma Medications. , 2010, , 677-688.		1
838	Exenatide is Non-inferior to Insulin in Reducing HbA _{1c} : An Integrated Analysis of 1423 Patients with Type 2 Diabetes. Postgraduate Medicine, 2010, 122, 118-128.	2.0	28
839	Effectiveness of blood pressure lowering: evidence-based comparisons between men and women. Expert Review of Cardiovascular Therapy, 2010, 8, 199-209.	1.5	16
840	ACE-Inhibition and Physical Function: Results From the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) Study. Journal of the American Medical Directors Association, 2010, 11, 26-32.	2.5	61
842	Effect of systemic medications on onset and progression of diabetic retinopathy. Nature Reviews Endocrinology, 2010, 6, 494-508.	9.6	42
844	Ocular Retinopathies and Clinical Control of Angiogenesis. , 2010, , 27-65.		1
845	Glucose, Obesity, Metabolic Syndrome, and Diabetes. Journal of the American College of Cardiology, 2010, 55, 283-293.	2.8	174
846	Hypertensive Treatment in Patients With Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2010, 8, 95-104.	1.3	4
847	Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure, 2010, 16, 475-539.	1.7	267
848	Section 3: Prevention of Ventricular Remodeling, Cardiac Dysfunction, and Heart Failure. Journal of Cardiac Failure, 2010, 16, e38-e43.	1.7	0
849	Angiotensin-Converting Enzyme Inhibitor Associated Cough: Deceptive Information from the Physicians' Desk Reference. American Journal of Medicine, 2010, 123, 1016-1030.	1.5	90
850	Insufficient control of morning home blood pressure in Japanese patients with hypertension associated with diabetes mellitus. Journal of Diabetes Investigation, 2010, 1, 266-272.	2.4	1

#	ARTICLE	IF	CITATIONS
851	NÃ©phropathie diabÃ©tique. , 2010, , 207-233.		0
852	Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. <i>Lancet, The</i> , 2010, 375, 906-915.	13.7	657
853	Î² blockers in hypertension. <i>Lancet, The</i> , 2010, 376, 415.	13.7	12
854	Î² blockers in hypertension â€” Author's reply. <i>Lancet, The</i> , 2010, 376, 415-416.	13.7	6
855	Effects of Î²-blockers on glucose and lipid metabolism. <i>Current Medical Research and Opinion</i> , 2010, 26, 615-629.	1.9	122
856	Current role of beta-blockers in the treatment of hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2599-2607.	1.8	52
857	ArtistÃ© Tablets (Carvedilol) for Hypertensive Patients in Japan. <i>Drugs in R and D</i> , 2011, 11, 191-205.	2.2	2
858	Pragmatic vs. explanatory: An adaptation of the PRECIS tool helps to judge the applicability of systematic reviews for daily practice. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1095-1101.	5.0	54
859	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324â€”168 participants from randomised trials. <i>Lancet Oncology, The</i> , 2011, 12, 65-82.	10.7	332
860	Heart Failure as a Consequence of Hypertension. , 2011, , 435-444.		0
862	Diabetes monitoring: risk factors, complications and management. <i>NursePrescribing</i> , 2011, 9, 122-130.	0.1	3
864	Reninâ€”angiotensinâ€”aldosterone system blockade and urinary albumin excretion in communityâ€”based patients with Typeâ€”2 diabetes: The Fremantle Diabetes Study. <i>Diabetic Medicine</i> , 2011, 28, 849-855.	2.3	2
865	Metabolic sequelae of Î²-blocker therapy: weighing in on the obesity epidemic?. <i>International Journal of Obesity</i> , 2011, 35, 1395-1403.	3.4	52
866	Blood Pressure Targets in Diabetes: Is This the Time for Change?â€”CON (Rebuttal). <i>Journal of Clinical Hypertension</i> , 2011, 13, 268-269.	2.0	1
867	Thiazide Diuretics and Î²-blockers in the Treatment of Hypertension in Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2011, 13, 296-300.	2.0	11
868	ACE inhibitors in cardiac surgery: current studies and controversies. <i>Hypertension Research</i> , 2011, 34, 15-22.	2.7	16
869	Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat. <i>Diabetologia</i> , 2011, 54, 2724-2735.	6.3	31
870	What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?. <i>Advances in Therapy</i> , 2011, 28, 716-727.	2.9	4

#	ARTICLE	IF	CITATIONS
871	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2011, 10, 22.	6.8	137
872	Can we bridge the gap? Knowledge and practices related to Diabetes Mellitus among general practitioners in a developing country: A cross sectional study. <i>Asia Pacific Family Medicine</i> , 2011, 10, 15.	0.4	9
873	The role of β -blockers in the management of hypertension: An Asian perspective. <i>Current Medical Research and Opinion</i> , 2011, 27, 1021-1033.	1.9	14
874	Management of Blood Pressure in Patients With Diabetes. <i>American Journal of Hypertension</i> , 2011, 24, 863-875.	2.0	33
875	General practice and social service partnership for better clinical outcomes, patient self efficacy and lifestyle behaviours of diabetic care: randomised control trial of a chronic care model. <i>Postgraduate Medical Journal</i> , 2011, 87, 688-693.	1.8	28
876	Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2011, 2, 17-26.	3.2	28
877	Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. <i>Journal of Hypertension</i> , 2011, 29, 1253-1269.	0.5	235
878	Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. <i>Nephron Clinical Practice</i> , 2011, 118, c71-c100.	2.3	23
879	A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. <i>Blood Pressure</i> , 2011, 20, 322-334.	1.5	9
880	Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. <i>European Heart Journal</i> , 2011, 32, 2247-2255.	2.2	39
881	Microvascular and Macrovascular Complications of Diabetes. <i>Clinical Diabetes</i> , 2011, 29, 116-122.	2.2	210
882	The Enhanced Effect of Atenolol on Hypertension in Metabolic Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2011, 9, 369-373.	1.3	1
883	Primary Prevention of Heart Failure. <i>ISRN Cardiology</i> , 2012, 2012, 1-15.	1.6	18
884	Prescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India. <i>International Journal of Hypertension</i> , 2012, 2012, 1-9.	1.3	26
885	Blockade of the renin-angiotensin system for the primary prevention of diabetic nephropathy. <i>Diabetes Management</i> , 2012, 2, 55-64.	0.5	1
886	Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. <i>BMJ, The</i> , 2012, 345, e5567-e5567.	6.0	76
887	Beta-blockers for hypertension. , 2012, , CD002003.		24
888	Ocular Blood Flow in Diabetes: Contribution to the Microvascular Lesions of Diabetic Retinopathy. , 2012, , 365-387.		0

#	ARTICLE	IF	CITATIONS
889	The Effect of Antihypertensive Drugs on Endothelial Function as Assessed by Flow-Mediated Vasodilation in Hypertensive Patients. <i>International Journal of Vascular Medicine</i> , 2012, 2012, 1-11.	1.0	19
890	Genetic Predisposition to High Blood Pressure Associates With Cardiovascular Complications Among Patients With Type 2 Diabetes. <i>Diabetes</i> , 2012, 61, 3026-3032.	0.6	12
891	Metabolic Syndrome: Definition and Therapeutic Implications. <i>Postgraduate Medicine</i> , 2012, 124, 21-30.	2.0	137
892	Neovascularization Is Attenuated With Aldosterone Synthase Inhibition in Rats With Retinopathy. <i>Hypertension</i> , 2012, 59, 607-613.	2.7	61
893	Hypertensive left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2012, 30, 2039-2046.	0.5	24
894	Diabetes and hypertension: the bad companions. <i>Lancet, The</i> , 2012, 380, 601-610.	13.7	498
895	Thiazolidinedioneâ€independent activation of peroxisome proliferatorâ€activated receptor β is a potential target for diabetic macrovascular complications. <i>Journal of Diabetes Investigation</i> , 2012, 3, 11-23.	2.4	2
896	Consistency with the Dietary Approaches to Stop Hypertension Diet among Adults with Diabetes. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2012, 112, 1798-1805.	0.8	6
898	The effect of the introduction of a standard monitoring protocol on the investigations performed on the metabolic control of type 2 diabetes at Addington Hospital Medical Outpatients Department, Durban, South Africa. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2012, 54, 151-155.	0.6	0
899	Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. <i>Kidney International</i> , 2012, 81, 586-594.	5.2	53
900	Beta-blockers for hypertension. , 2012, 11, CD002003.		80
901	Antihypertensive agents for preventing diabetic kidney disease. <i>The Cochrane Library</i> , 2012, 12, CD004136.	2.8	68
902	Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. <i>Hypertension Research</i> , 2012, 35, 4-16.	2.7	159
903	Managing blood pressure and lipids in diabetes in primary care. <i>Practice Nursing</i> , 2012, 23, 82-87.	0.1	1
904	Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats. <i>Regulatory Toxicology and Pharmacology</i> , 2012, 62, 7-15.	2.7	13
905	Alternative pathways in the development of diabetic retinopathy: the reninâ€angiotensin and kallikreinâ€kinin systems. <i>Australasian journal of optometry, The</i> , 2012, 95, 282-289.	1.3	15
906	Reno-protective effects of reninâ€angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. <i>Diabetologia</i> , 2012, 55, 566-578.	6.3	118
907	Inhibitory Effects of Azelnidipine Tablets on Morning Hypertension. <i>Drugs in R and D</i> , 2013, 13, 63-73.	2.2	18

#	ARTICLE	IF	CITATIONS
908	Impact of Heart Rate on Central Hemodynamics and Stroke: A Meta-Analysis of β -Blocker Trials. American Journal of Hypertension, 2013, 26, 118-125.	2.0	21
909	Treatment Strategies for the Prevention of Heart Failure. Current Heart Failure Reports, 2013, 10, 331-340.	3.3	9
910	Diabetic population mortality and cardiovascular risk attributable to hypertension: A decade follow-up from the Tehran Lipid and Glucose Study. Blood Pressure, 2013, 22, 317-324.	1.5	8
911	Management of hypertension in patients with type 2 diabetes mellitus. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2013, 55, 41-44.	0.6	0
912	Pharmacologic Management of Hypertension. , 2013, , 474-489.		4
913	The past, present and future of renin-angiotensin aldosterone system inhibition. International Journal of Cardiology, 2013, 167, 1677-1687.	1.7	97
914	Cardioselective Beta-Blocker: Pharmacological Evidence and Their Influence on Exercise Capacity. Cardiovascular Therapeutics, 2013, 31, 76-83.	2.5	79
915	Antagonistas de los receptores de la angiotensina II en el tratamiento de la hipertensi3n arterial, las enfermedades cardiovasculares y las renales. Realidad y futuro. Hipertension Y Riesgo Vascular, 2013, 30, 3-10.	0.6	0
916	The Role of Diet in the Prevention and Treatment of Diabetes. , 2013, , 615-628.		0
917	Optimization and validation of a MEKC method assisted by Box-Behnken Design for fast and simultaneous determination of nitrendipine and atenolol in new antihypertensive combination tablets. Analytical Methods, 2013, 5, 3353.	2.7	1
918	Comparison of the Hypoglycemic Effect of Acarbose Monotherapy in Patients With Type 2 Diabetes Mellitus Consuming an Eastern or Western Diet: A Systematic Meta-analysis. Clinical Therapeutics, 2013, 35, 880-899.	2.5	71
919	The Lower, the Better?. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 135-138.	2.2	2
920	Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ, The, 2013, 347, f5680-f5680.	6.0	209
921	Choice of anti-hypertensive agents in diabetic subjects. Diabetes and Vascular Disease Research, 2013, 10, 385-396.	2.0	17
922	Hypertension Management in the High Cardiovascular Risk Population. International Journal of Hypertension, 2013, 2013, 1-7.	1.3	11
923	Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials. ISRN Cardiology, 2013, 2013, 1-8.	1.6	28
924	Benefits of Early Hypertension Control on Cardiovascular Outcomes in Patients With Diabetes. Diabetes Care, 2013, 36, 322-327.	8.6	20
925	Cardinal Role of the Intrarenal Renin-Angiotensin System in the Pathogenesis of Diabetic Nephropathy. Journal of Investigative Medicine, 2013, 61, 256-264.	1.6	53

#	ARTICLE	IF	CITATIONS
926	Inhibition of Renin-Angiotensin System. <i>Journal of Investigative Medicine</i> , 2013, 61, 551-557.	1.6	18
927	Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 198-201.	0.5	7
928	Ischemic Heart Disease in Hypertension. , 2013, , 253-261.		0
929	Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 148.	1.7	36
930	Chapter 7. Hypertension complicated by other diseases. <i>Hypertension Research</i> , 2014, 37, 315-324.	2.7	2
931	Pulse-Waveform Analysis of Normal Population using Laser Speckle Flowgraphy. <i>Current Eye Research</i> , 2014, 39, 1207-1215.	1.5	58
932	Lifestyle Factors in Hypertension Drug Research: Systematic Analysis of Articles in a Leading Cochrane Report. <i>International Journal of Hypertension</i> , 2014, 2014, 1-10.	1.3	11
933	Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease. <i>International Journal of Hypertension</i> , 2014, 2014, 1-7.	1.3	24
934	Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 4.	1.7	12
935	Cardiovascular drugs that increase the risk of new-onset diabetes. <i>American Heart Journal</i> , 2014, 167, 421-428.	2.7	30
936	β-Blockers in Hypertension: Studies and Meta-analyses Over the Years. <i>Canadian Journal of Cardiology</i> , 2014, 30, S16-S22.	1.7	51
938	Néphropathie diabétique. , 2014, , 229-250.		0
939	Désordres cliniques et biologiques associés. , 2014, , 71-88.		0
940	Hypertension in Diabetes Mellitus. , 2014, , 119-134.		0
941	Antihypertensive and Other Treatments in Early Stages of Diabetic Nephropathy. , 2014, , 229-239.		0
942	Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. , 2014, 142, 375-415.		437
943	The effect of RAAS blockade on the progression of diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2014, 10, 77-87.	9.6	128
944	New Hypertension Guidelines: A View from Latin America. <i>Journal of Clinical Hypertension</i> , 2014, 16, 261-262.	2.0	0

#	ARTICLE	IF	CITATIONS
946	General aspects of diabetes mellitus. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 211-222.	1.8	160
947	Treating hypertension in type 2 diabetes. Expert Opinion on Pharmacotherapy, 2014, 15, 2131-2140.	1.8	9
949	Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats. Diabetology and Metabolic Syndrome, 2014, 6, 57.	2.7	17
950	Atenolol vs Nonatenolol β -Blockers for the Treatment of Hypertension: A Meta-analysis. Canadian Journal of Cardiology, 2014, 30, S47-S53.	1.7	60
951	Concerns About the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure & Blood Pressure Panel Member Recommendations and Their Relevance to Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2014, 12, 251-254.	1.3	0
952	Rationale, design, and implementation of a cluster randomized trial using certified diabetes educators to intensify treatment for glycemia, blood pressure and lipid control: REMEDIES 4D. Contemporary Clinical Trials, 2014, 39, 124-131.	1.8	9
953	Vascular Endothelial Function. , 2014, , 1-37.		1
954	Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors. Diabetes Care, 2014, 37, 1660-1667.	8.6	68
955	Prevalence and risk factors for diabetic retinopathy in Asian Indians with young onset Type 1 and Type 2 Diabetes. Journal of Diabetes and Its Complications, 2014, 28, 291-297.	2.3	68
956	Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease. Advances in Chronic Kidney Disease, 2014, 21, 281-286.	1.4	51
959	Prescription medication burden in patients with newly diagnosed diabetes: A SURveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study. Journal of the American Pharmacists Association: JAPhA, 2014, 54, 374-382.	1.5	24
960	Survival on Dialysis Among American Indians and Alaska Natives With Diabetes in the United States, 1995-2010. American Journal of Public Health, 2014, 104, S490-S495.	2.7	13
961	The role of point of care testing in diabetes management. British Journal of Health Care Management, 2015, 21, 63-67.	0.2	3
963	Comparison of intrarenal renin-angiotensin system activity in diabetic versus non-diabetic patients with overt proteinuria. Nephrology, 2015, 20, 279-285.	1.6	10
964	Feasibility and impact of implementing a private care system's diabetes quality improvement intervention in the safety net: a cluster-randomized trial. Implementation Science, 2015, 10, 83.	6.9	17
965	Effects of blood pressure-lowering on outcome incidence in hypertension. Journal of Hypertension, 2015, 33, 1321-1341.	0.5	123
966	Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences. Journal of Clinical Medicine, 2015, 4, 1908-1937.	2.4	40
968	Effects of grape seed proanthocyanidin extract on renal injury in type 2 diabetic rats. Molecular Medicine Reports, 2015, 11, 645-652.	2.4	37

#	ARTICLE	IF	CITATIONS
969	Intraclass Differences Among Antihypertensive Drugs. Annual Review of Pharmacology and Toxicology, 2015, 55, 333-352.	9.4	14
970	Vascular Endothelial Function. , 2015, , 89-120.		5
971	Vascular Complications of Diabetes Mellitus. , 2015, , 1541-1593.		0
972	Blood pressure control for diabetic retinopathy. The Cochrane Library, 2015, 1, CD006127.	2.8	91
973	Microalbuminuria: A parameter that has changed diabetes care. Diabetes Research and Clinical Practice, 2015, 107, 1-8.	2.8	75
974	Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology, the, 2015, 3, 263-274.	11.4	99
975	Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years: a population-based cohort study. Age and Ageing, 2015, 44, 566-573.	1.6	17
976	Effects of blood pressure lowering on outcome incidence in hypertension. Journal of Hypertension, 2015, 33, 195-211.	0.5	221
977	Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1175-1184.	1.7	6
978	Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diabetes and Vascular Disease Research, 2015, 12, 352-358.	2.0	68
979	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
980	Antianginal drugs. , 2016, , 530-532.		0
981	Timeline of History of Hypertension Treatment. Frontiers in Cardiovascular Medicine, 2016, 3, 3.	2.4	65
982	Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Medicine, 2016, 13, e1001971.	8.4	75
983	Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes, Obesity and Metabolism, 2016, 18, 766-774.	4.4	24
984	Effects of the behavior of elderly type 2 diabetic patients and their relatives as caregivers on diabetes follow-up parameters in <sc>B</sc>olu, <sc>T</sc>urkey. Geriatrics and Gerontology International, 2016, 16, 182-190.	1.5	1
985	Peripheral vasoconstriction induced by β_2 -adrenoceptor blockers: a systematic review and a network meta-analysis. British Journal of Clinical Pharmacology, 2016, 82, 549-560.	2.4	19
986	Vascular Complications of Diabetes. Circulation Research, 2016, 118, 1771-1785.	4.5	262

#	ARTICLE	IF	CITATIONS
987	Evolution of pharmacological obesity treatments: focus on adverse sideâ€effect profiles. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 558-570.	4.4	134
988	Several Aspects of Internet and Web-Based Technology in Diabetes Management. <i>Diabetes Spectrum</i> , 2016, 29, 245-248.	1.0	3
990	The Role of Beta-Blockers in the Treatment of Hypertension. <i>Advances in Experimental Medicine and Biology</i> , 2016, 956, 149-166.	1.6	35
992	Effects of blood-pressure-lowering treatment in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1921-1932.	0.5	74
993	Novel insight into the dangerous connection between diabetes and heart failure. <i>Herz</i> , 2016, 41, 201-207.	1.1	12
994	Intensive Glycemic Therapy in Patients With Type 2 Diabetes on β -Blockers. <i>Diabetes Care</i> , 2016, 39, 1818-1826.	8.6	14
995	Early specialist care for diabetes: who benefits most? A propensity scoreâ€matched cohort study. <i>Diabetic Medicine</i> , 2016, 33, 111-118.	2.3	8
996	Hypertension in type 2 diabetes: impact of glucose-lowering medications. <i>Cardiovascular Endocrinology</i> , 2016, 5, 137-143.	0.8	0
997	Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetesâ€Network meta-analysis of randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1192-1200.	2.3	31
998	Managing hypertension in type 2 diabetes mellitus. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 445-454.	4.7	36
999	Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure â€ meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2016, 34, 373-384.	0.5	75
1000	Comparison of the effects of levocetirizine and losartan on diabetic nephropathy and vascular dysfunction in streptozotocin-induced diabetic rats. <i>European Journal of Pharmacology</i> , 2016, 780, 82-92.	3.5	19
1001	Adjusting the 17β -Estradiol-to-Androgen Ratio Ameliorates Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3035-3050.	6.1	30
1002	Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. <i>Lancet, The</i> , 2016, 387, 957-967.	13.7	2,464
1003	Systemic oxygen therapy versus oral enalapril for treatment of diabetic macular ischemia: a randomized controlled trial. <i>International Ophthalmology</i> , 2016, 36, 225-235.	1.4	2
1004	Antihypertensive Drugs and Male Sexual Dysfunction. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 233-244.	2.0	32
1006	Blood pressure control in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2017, 16, 3.	6.8	77
1007	Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease. <i>Journal of Diabetes Investigation</i> , 2017, 8, 261-271.	2.4	37

#	ARTICLE	IF	CITATIONS
1008	Beta-blockers for hypertension. The Cochrane Library, 2017, 2017, CD002003.	2.8	205
1009	Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. <i>Nature Reviews Endocrinology</i> , 2017, 13, 365-374.	9.6	29
1010	NOD2 promotes endothelial-to-mesenchymal transition of glomerular endothelial cells via MEK/ERK signaling pathway in diabetic nephropathy. <i>Biochemical and Biophysical Research Communications</i> , 2017, 484, 435-441.	2.1	49
1011	Epidemiology in diabetes mellitus and cardiovascular disease. <i>Cardiovascular Endocrinology</i> , 2017, 6, 8-16.	0.8	109
1012	Blood pressure management in patients with type 2 diabetes mellitus. <i>Hypertension Research</i> , 2017, 40, 721-729.	2.7	7
1013	Comparative efficacy of $\hat{\text{I}}^2$ -blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 394-401.	2.3	19
1014	Risk of Cardiovascular Events in Patients With Diabetes Mellitus on $\hat{\text{I}}^2$ -Blockers. <i>Hypertension</i> , 2017, 70, 103-110.	2.7	61
1015	Managing Hypertension in the Elderly: What is Different, What is the Same?. <i>Current Cardiovascular Risk Reports</i> , 2017, 11, 1.	2.0	1
1016	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2017, 35, 922-944.	0.5	173
1017	The Real Role of $\hat{\text{I}}^2$ -Blockers in Daily Cardiovascular Therapy. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 361-373.	2.2	79
1018	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 951-964.	11.4	228
1019	Diabetes Mellitus and Control of Cardiovascular Disease Risk Factors. <i>Circulation</i> , 2017, 136, 1204-1206.	1.6	1
1020	Managing Hypertension in Patients Aged 75 Years and Older. <i>Current Hypertension Reports</i> , 2017, 19, 88.	3.5	4
1021	Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada. <i>BMJ Open</i> , 2017, 7, e013808.	1.9	7
1022	Managing Hypertension in the Elderly: What is Different, What is the Same?. <i>Current Hypertension Reports</i> , 2017, 19, 67.	3.5	5
1023	Pharmacotherapy for hypertension in adults aged 18 to 59 years. The Cochrane Library, 2017, 2017, CD008276.	2.8	32
1024	Mechanistic Insights into Pathological Changes in the Diabetic Retina. <i>American Journal of Pathology</i> , 2017, 187, 9-19.	3.8	157
1025	Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine. <i>Future Cardiology</i> , 2017, 13, 143-151.	1.2	1

#	ARTICLE	IF	CITATIONS
1026	Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. <i>International Journal of Chronic Diseases</i> , 2017, 2017, 1-11.	1.0	1
1027	Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 128.	4.7	43
1028	The Role of Diet in the Prevention and Treatment of Diabetes. , 2017, , 691-707.		0
1029	Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?. <i>American Journal of Kidney Diseases</i> , 2018, 72, 728-744.	1.9	58
1030	Update of pathophysiology and management of diabetic kidney disease. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 662-675.	1.7	325
1031	Updates to Adherence to Hypertension Medications. <i>Current Hypertension Reports</i> , 2018, 20, 34.	3.5	19
1032	Pharmacological intervention in hypertension using beta-blockers: Real-world evidence for long-term effectiveness. <i>Pharmacological Research</i> , 2018, 130, 191-197.	7.1	13
1033	Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease. <i>Pharmacotherapy</i> , 2018, 38, 309-318.	2.6	35
1034	Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2018, 137, 137-148.	2.8	114
1035	First-line drugs for hypertension. <i>The Cochrane Library</i> , 2018, 2018, CD001841.	2.8	197
1036	Pharmacotherapeutic strategies for treating hypertension in patients with obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 643-651.	1.8	9
1037	Evaluation of a Behavioral Intervention With Multiple Components Among Low-Income and Uninsured Adults With Obesity and Diabetes. <i>American Journal of Health Promotion</i> , 2018, 32, 409-422.	1.7	18
1038	Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension. <i>Journal of Diabetes Investigation</i> , 2018, 9, 875-881.	2.4	15
1039	Effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review. <i>JBIC Database of Systematic Reviews and Implementation Reports</i> , 2018, 16, 1823-1873.	1.7	17
1040	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. <i>The Cochrane Library</i> , 2018, 9, CD011798.	2.8	48
1041	Hypertension Management in Diabetes: 2018 Update. <i>Diabetes Spectrum</i> , 2018, 31, 218-224.	1.0	51
1042	Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial. <i>PLoS ONE</i> , 2018, 13, e0195898.	2.5	25
1043	Hypertension in Ischemic Heart Disease. , 2018, , 288-297.		0

#	ARTICLE	IF	CITATIONS
1044	The impact of insulin pump therapy to oxidative stress in patients with diabetic nephropathy. <i>European Journal of Medical Research</i> , 2018, 23, 7.	2.2	14
1045	Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality. <i>Journal of Hypertension</i> , 2018, 36, 1637-1647.	0.5	59
1046	Role of Beta-blockers in Cardiovascular Disease in 2019. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 844-852.	0.6	18
1047	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). <i>Hypertension Research</i> , 2019, 42, 1235-1481.	2.7	1,047
1048	The Kidney in Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 191-210.	0.1	0
1049	Papel de los bloqueadores beta en la enfermedad cardiovascular en 2019. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 844-852.	1.2	20
1050	Treatment of Hypertension in Chronic Kidney Disease. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 239-255.	0.1	1
1051	Antihypertensive drugs and the risks of cancer: More fakes than facts. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1323-1326.	1.8	5
1052	Neuroprotective effect of levetiracetam in mouse diabetic retinopathy: Effect on glucose transporter-1 and GAP43 expression. <i>Life Sciences</i> , 2019, 232, 116588.	4.3	29
1053	Real-World Data on the Incidence of Macrovascular Complications in Japanese Patients with Type 2 Diabetes: The Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project. <i>Diabetes Therapy</i> , 2019, 10, 1099-1111.	2.5	4
1054	Standards of medical care for type 2 diabetes in China 2019. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3158.	4.0	404
1055	Epidemiology of Diabetes Mellitus and Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2019, 21, 21.	2.9	363
1056	Blood Pressure-Lowering Treatment and the Prevention of Heart Failure: Differences and Similarities of Antihypertensive Drug Classes. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 285-298.	0.1	0
1057	The effects of renin-angiotensin system inhibitors on mortality, cardiovascular events, and renal events in hypertensive patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Hypertension Research</i> , 2019, 42, 669-680.	2.7	8
1058	Effect of Renin-Angiotensin System Blockade on Mortality in Korean Hypertensive Patients with Proteinuria. <i>Electrolyte and Blood Pressure</i> , 2019, 17, 25.	1.8	2
1059	Acute, local infusion of angiotensin II impairs microvascular and metabolic insulin sensitivity in skeletal muscle. <i>Cardiovascular Research</i> , 2019, 115, 590-601.	3.8	8
1060	Evaluation and Treatment of Hypertension. , 2019, , 251-270.		0
1061	Diabetes Comorbidity Increases Risk of Postoperative Complications in Traumatic Thoracic Vertebral Fracture Repair: A Propensity Score Matched Analysis. <i>World Neurosurgery</i> , 2019, 121, e792-e797.	1.3	4

#	ARTICLE	IF	CITATIONS
1062	Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2019, 20, 277-294.	1.8	31
1063	Change in Proteinuria or Albuminuria as a Surrogate for Cardiovascular and Other Major Clinical Outcomes: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2019, 35, 77-91.	1.7	17
1064	Pharmacotherapy for hypertension in adults 60 years or older. The Cochrane Library, 2020, 2020, CDO000028.	2.8	26
1065	Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study. Journal of Pharmaceutical Health Care and Sciences, 2020, 6, 13.	1.0	7
1066	Diabetic Kidney Disease: Challenges, Advances, and Opportunities. Kidney Diseases (Basel, Switzerland), 2020, 6, 215-225.	2.5	98
1067	Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. Journal of Hypertension, 2020, 38, 1669-1681.	0.5	36
1068	Japanese Clinical Practice Guideline for Diabetes 2019. Journal of Diabetes Investigation, 2020, 11, 1020-1076.	2.4	159
1069	Japanese Clinical Practice Guideline for Diabetes 2019. Diabetology International, 2020, 11, 165-223.	1.4	266
1070	Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States. Journal of Clinical Hypertension, 2020, 22, 2084-2092.	2.0	3
1071	100 most-cited articles on diabetic retinopathy. British Journal of Ophthalmology, 2021, 105, 1329-1336.	3.9	13
1072	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	27.0	228
1073	Cost-effectiveness of intensive interventions compared to standard care in individuals with type 2 diabetes: A systematic review and critical appraisal of decision-analytic models. Diabetes Research and Clinical Practice, 2020, 161, 108073.	2.8	3
1074	Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney International, 2021, 99, 256-266.	5.2	46
1075	Effect of a nurse-led lifestyle choice and coaching intervention on systolic blood pressure among type 2 diabetic patients with a high atherosclerotic cardiovascular risk: study protocol for a cluster-randomized trial. Trials, 2021, 22, 133.	1.6	1
1076	System Architecture for "Support Through Mobile Messaging and Digital Health Technology for Diabetes" (SuMMiT-D): Design and Performance in Pilot and Randomized Controlled Feasibility Studies. JMIR Formative Research, 2021, 5, e18460.	1.4	4
1077	Î²-blocker use and risk of all-cause mortality in patients with coronary heart disease: effect modification by serum vitamin A. European Journal of Preventive Cardiology, 2022, 28, 1897-1902.	1.8	5
1079	Islet microangiopathy and augmented Î² cell loss in Japanese nonobese type 2 diabetes patients who died of acute myocardial infarction. Journal of Diabetes Investigation, 2021, 12, 2149.	2.4	4
1080	Diabetic retinopathy in newly diagnosed Type 2 diabetes mellitus: Prevalence and predictors of progression; a national primary network study. Diabetes Research and Clinical Practice, 2021, 175, 108776.	2.8	9

#	ARTICLE	IF	CITATIONS
1081	Evolution of Type 2 Diabetes Management from a Glucentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. <i>Drugs</i> , 2021, 81, 1373-1379.	10.9	13
1082	Effect of Third-Generation Beta Blockers on Weight Loss in a Population of Overweight-Obese Subjects in a Controlled Dietary Regimen. <i>Journal of Nutrition and Metabolism</i> , 2021, 2021, 1-7.	1.8	7
1085	ACE Inhibitors and Angiotensin II Receptor Antagonists. <i>Handbook of Experimental Pharmacology</i> , 2005, , 407-442.	1.8	29
1087	Microalbuminuria, Blood Pressure and Diabetic Renal Disease: Origin and Development of Ideas. , 2000, , 655-706.		9
1088	Diabetes in the Elderly. , 2000, , 181-203.		18
1089	Hypertension in Chronic Kidney Disease. , 2004, , 371-387.		13
1090	Oxidative and Glycooxidative Stress in Diabetic Nephropathy. , 2006, , 151-172.		5
1091	Adherence to Practice Guidelines for People with Diabetes Mellitus. , 2008, , 235-249.		1
1093	A State-Based Model for Management of Type II Diabetes. <i>Studies in Computational Intelligence</i> , 2007, , 27-61.	0.9	3
1094	Ischemic Heart Disease in Hypertension. , 2007, , 327-339.		3
1095	Treatment of Hypertension in the Patient with Cardiovascular Disease * *Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ACS, acute coronary syndromes; AF, atrial fibrillation; MI, myocardial infarction; ARB, angiotensin II type 1 receptor blocker; BB, beta-adrenergic receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; CHD, coronary heart disease; DM, diabetes mellitus; DBP, diastolic blood pressure; ESRD, end-stage renal disease; HF, heart failure;. , 2007, , 625-646.		4
1097	Î ² -Blocking Agents. , 2009, , 1-37.		5
1098	Complications of Diabetes Mellitus. , 2011, , 1462-1551.		8
1099	Pharmacotherapy of hypertension in patients with pre-dialysis chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1201-1217.	1.8	2
1100	Risk factors in the elderly. , 2005, , 606-628.		1
1101	A review of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. <i>Current Opinion in Cardiology</i> , 1999, 14, 161.	1.8	24
1102	Angiotensin converting enzyme inhibitors: first line therapy in patients with diabetic hypertension?. <i>Current Opinion in Nephrology and Hypertension</i> , 1999, 8, 333-334.	2.0	4
1103	Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective. <i>Journal of Hypertension</i> , 2020, 38, 1005-1015.	0.5	8

#	ARTICLE	IF	CITATIONS
1104	The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. <i>Journal of Hypertension</i> , 2010, 28, 2357-2369.	0.5	73
1105	Laparoscopic sleeve gastrectomy in the treatment of gastrointestinal stroma tumours in morbid obese patients. <i>BMJ Case Reports</i> , 2009, 2009, bcr0620080204-bcr0620080204.	0.5	9
1106	Associations between multimorbidity and glycaemia (HbA1c) in people with type 2 diabetes: cross-sectional study in Australian general practice. <i>BMJ Open</i> , 2020, 10, e039625.	1.9	8
1107	A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy. <i>CardioRenal Medicine</i> , 2020, 10, 392-401.	1.9	18
1108	The Status of Hypertension Management in Japan in 2000.. <i>Hypertension Research</i> , 2002, 25, 717-725.	2.7	36
1109	Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0125519.	2.5	8
1110	The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease. <i>PLoS ONE</i> , 2017, 12, e0170874.	2.5	24
1111	Tratamento de Diabetes e HipertensãŁo no Paciente Obeso. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2002, 46, 137-142.	1.3	8
1113	ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1100-1108.	6.1	110
1114	Impact of bisoprolol therapy on brain perfusion in patients with metabolic syndrome. <i>Arterial Hypertension (Russian Federation)</i> , 2003, 9, 160-163.	0.4	1
1115	The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence. <i>Protein and Peptide Letters</i> , 2020, 27, 463-475.	0.9	21
1116	Hypertension and Diabetes. , 2007, , 417-436.		1
1117	Obesity and Hypertension. <i>Fundamental and Clinical Cardiology</i> , 2006, , 33-50.	0.0	1
1118	Relationship Between Metabolic Syndrome and Risk of Chronic Complications in Koreans with Type 2 Diabetes. <i>Korean Diabetes Journal</i> , 2009, 33, 392.	0.8	7
1119	Perspectives on the Attitudes of Healthcare Professionals toward Diabetes in Community Health Settings in United Arab Emirates. <i>Journal of Diabetes Mellitus</i> , 2015, 05, 1-11.	0.3	7
1120	Attenuated levels of pro-inflammatory markers in diabetic retinopathy patients undergoing treatment with antihyperglycemic and antihypertensive drugs. <i>Clinics</i> , 2013, 68, 185-191.	1.5	14
1121	Scientific Basis for New Guidelines for the Treatment of Hypertension in Type 2 Diabetes. , 2000, , 611-621.		0
1122	Arterielle Hypertonie. , 2000, , 533-546.		0

#	ARTICLE	IF	CITATIONS
1123	Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria. , 2000, , 441-459.		5
1124	Arterielle Hypertonie. , 2000, , 259-268.		0
1125	Weitere kardiovaskuläre Risikofaktoren. , 2000, , 269-291.		0
1126	Diabetes, Hypertension, and Kidney Disease in the Pima Indians. , 2000, , 395-405.		0
1127	Diabetic Nephropathy in Patients with Type II Diabetes. , 2000, , 77-89.		0
1128	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2000, , 23-33.		0
1130	Retinopathy in Relation to Albuminuria and Blood Pressure in IDDM. , 2000, , 29-38.		0
1131	Update of the Latest Intervention Trials in Hypertension and Type 2 Diabetes. , 2000, , 601-610.		0
1132	Fettstoffwechsel, Übergewicht und Ernährung, Diabetes. , 2000, , 239-257.		0
1133	HOPE for all people with diabetes?. Diabetic Medicine, 2000, 17, 9-10.	2.3	2
1134	Evaluative and epidemiological approaches of ACE therapy. , 2001, , 47-70.		1
1135	ACE and diabetes. , 2001, , 177-184.		0
1136	Antihypertensive Therapie bei Diabetes mellitus. , 2001, , 191-206.		1
1137	Medikamentöse Behandlung der arteriellen Hypertonie bei Zusatzerkrankungen. , 2001, , 360-391.		0
1138	The Effect of Hypertension in Diabetes. Advances in Experimental Medicine and Biology, 2001, 498, 115-117.	1.6	0
1139	Hemmer des Renin-Angiotensin-Systems. , 2001, , 320-341.		0
1140	Diabetische Retinopathie. , 2001, , 207-218.		0
1141	Antihypertensive Therapy: Progression of Renal Injury. , 2001, , 208-236.		0

#	ARTICLE	IF	CITATIONS
1142	Sympatholytika. , 2001, , 283-304.		0
1143	Medical Nutrition Therapy for Diabetes. , 2001, , 167-193.		0
1144	ACE-Hemmer und Angiotensin-rezeptorantagonisten. , 2001, , 51-64.		0
1145	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2001, , 72-88.		0
1146	Diabetische Nephropathie. Pharma-Kritik (discontinued), 2001, 23, .	0.0	0
1147	Microalbuminuria in Perspectives. , 2002, , 105-120.		2
1148	2.ç³-â°¿ç—...ã«ãšãšã,ã†ã•è,,^ç-¾æ,£ã•ãšã-¾ç-. The Journal of the Japanese Society of Internal Medicine, 2002, 90, 94-99		0
1149	Myocardial Dysfunction in the Perioperative Period. , 2002, , 93-105.		0
1150	Hypertension, Diabetes and the Heart. , 2002, , 65-84.		0
1151	Management of type 2 diabetes. , 2002, , 1-24.		0
1152	Blutdruckbehandlung bei Diabetes mellitus. Pharma-Kritik (discontinued), 2002, 24, .	0.0	0
1154	Antihypertensive therapy: Progression of Renal Injury. , 2003, , 209-240.		0
1155	Diabetic Microangiopathy. , 2003, , 571-587.		0
1156	Hypertension in Type 2 Diabetes Mellitus. , 2003, , 63-84.		1
1157	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2003, , 67-88.		0
1158	Transmural Pressure Control of Prorenin Processing and Secretion in Diabetic Rat Juxtaglomerular Cells.. Hypertension Research, 2003, 26, 493-501.	2.7	2
1159	3.ç³-â°¿ç—...æ€šè³çç-†ã•ãšãšãžã•è†ãš. The Journal of the Japanese Society of Internal Medicine, 2003, 92, 55-59.		0
1163	Angina. , 2003, , 39-53.		0

#	ARTICLE	IF	CITATIONS
1166	Inhibitors of the RAS: Evidence-Based Medicine. Handbook of Experimental Pharmacology, 2004, , 545-592.	1.8	0
1167	Clinical Pharmacology of Angiotensin II Receptor Antagonists. Handbook of Experimental Pharmacology, 2004, , 453-484.	1.8	0
1168	Combined Blockade of the Renin Angiotensin System with ACE Inhibitors and AT1 Receptor Antagonists. Handbook of Experimental Pharmacology, 2004, , 485-516.	1.8	0
1169	Herz, GefÄÄÙe, Lunge. , 2004, , 81-196.		0
1170	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2004, , 179-206.		0
1171	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2004, , 88-114.		0
1173	Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events. , 2005, , 543-556.		0
1174	Obesity and Hypertension: Impact on Cardiovascular and Renal Systems. , 2005, , 464-474.		0
1175	A Attitudes Regarding Hypertension Among Older African-American Adults. , 2005, , 429-450.		0
1177	Intervention in high risk groups: hypertension. , 2005, , 865-892.		0
1179	Antianginal drugs. , 2006, , 260-263.		0
1180	Angiotensin II antagonists, diabetes and metabolic syndrome. , 2006, , 99-109.		0
1181	Type 2 Diabetes. Fundamental and Clinical Cardiology, 2006, , 187-254.	0.0	0
1182	Beta Blockers in Hypertension. , 2007, , 959-970.		0
1183	Goal-Oriented Hypertension Management in Diabetic and Nondiabetic Patients. , 2007, , 205-222.		0
1184	Hypertension Management. Endocrine Practice, 2007, 13, 35-40.	2.1	2
1185	Sravnenie effektivnosti moksonidina i metoprololau patsientov s arterial'noy gipertoniey i sakharnymdiabetom 2 tipa (vliyanie na arterial'noe davlenie i metabolicheskie parametry). Obesity and Metabolism, 2007, 4, 38-39.	1.2	0
1188	Wat is de eerste keus bij behandeling van hypertensie bij type 2 diabetes?. , 2009, , 57-62.		0

#	ARTICLE	IF	CITATIONS
1190	Antihypertensive Drugs. , 2009, , 198-234.		0
1192	Modeling the Value for Money of Changing Clinical Practice Change. Medical Care, 2009, 47, 1053-1061.	2.4	6
1194	Th�rapeutique des d�sordres associ�s. , 2010, , 175-189.		0
1195	Microvascular Complications of Diabetes. , 2010, , 355-357.e2.		0
1196	D�sordres cliniques et biologiques associ�s. , 2010, , 77-98.		0
1197	Wat is de eerste keus bij behandeling van hypertensie bij type 2 diabetes?. , 2010, , 42-47.		0
1198	Preventive Medicine and New Therapeutic Modalities for Diabetic Retinopathy. Trends in the Sciences, 2010, 15, 26-32.	0.0	0
1199	Systemic and Ocular Factors Influencing Diabetic Retinopathy. , 2010, , 77-103.		0
1201	Hypertension in Chronic Kidney Disease. , 2011, , 397-418.		2
1203	Cardiovascular Pharmacology. , 2011, , 235-295.		2
1204	Diabetes monitoring and management. Independent Nurse, 2012, 2012, .	0.1	0
1205	A Stepped Care Approach to the Management of Chronic Kidney Disease. , 2012, , 2205-2239.		1
1207	Impact of Hypertension on Type 2 Diabetes in Mysore Population of South India. International Journal of Clinical Medicine, 2013, 04, 561-570.	0.2	1
1208	Hypertension in Chronic Kidney Disease. , 2013, , 323-342.		1
1209	Vascular Complications of Diabetes Mellitus. , 2014, , 1-65.		0
1210	Th�rapeutique des d�sordres associ�s. , 2014, , 189-201.		0
1211	Changing Concepts on the Role of Blood Pressure Reduction in Stroke Prevention with the Focus on �-Blocking Agents. , 2014, , 465-473.		0
1213	Treatment of Type 2 Diabetes Mellitus: Which Treatment Options are Best Suited for our Patients?. Endocrine Practice, 1998, 4, 425-426.	2.1	0

#	ARTICLE	IF	CITATIONS
1214	UKPDS: A Faltering Success. <i>Endocrine Practice</i> , 1998, 4, 428-429.	2.1	0
1215	Nephroprotektion durch Antihypertensiva. , 1999, , 185-201.		0
1216	Diabetische Nephropathie. , 1999, , 485-546.		1
1217	Treating type 2 diabetes. <i>BMJ: British Medical Journal</i> , 1999, 318, 666-666.	2.3	0
1218	Diabetes mellitus and anaesthesia. <i>Current Opinion in Anaesthesiology</i> , 1999, 12, 343-347.	2.0	4
1219	Diabetes and hypertension: an update. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 1999, 6, 245.	0.6	0
1220	Endocrine Heart Diseases. <i>Contemporary Cardiology</i> , 2015, , 571-591.	0.1	0
1221	Hypertension Controversies. <i>Contemporary Cardiology</i> , 2015, , 261-281.	0.1	0
1222	Beta-Blocker Controversies. <i>Contemporary Cardiology</i> , 2015, , 69-83.	0.1	0
1223	The Glycemic Consequences of Antihypertensive Medications. , 2015, , 935-948.		0
1225	Blood Pressure Control and Primary Prevention of Stroke: Summary of Clinical Trial Data. , 2016, , 39-59.		0
1229	Five Years Trends in Antihypertensive Monotherapy and Blood Pressure Control in Patients Referred to Tertiary Care Centre. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1231	Endocrinological Issues. , 2019, , 203-224.		0
1232	Prise en charge de la maladie rénale diabétique. , 2019, , 313-343.		0
1233	Thérapeutique des dysordres associés. , 2019, , 253-267.		0
1234	Dysordres cliniques et biologiques associés. , 2019, , 91-110.		0
1235	The Peculiarity of Process and Treatment of Arterial Hypertension in Patients with Type 2 Diabetes Mellitus. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 623-634.	0.8	1
1236	Primary Hypertension. , 2020, , 125-133.		0

#	ARTICLE	IF	CITATIONS
1237	Cardiodiabetology: Reducing Risks to Optimize Cardiovascular Disease Outcomes. Contemporary Cardiology, 2021, , 227-248.	0.1	0
1238	Epidemiology and Genetics of Diabetic Retinopathy. , 2020, , 1-20.		0
1242	Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication. Cardiovascular Endocrinology and Metabolism, 2021, 10, 31-36.	1.1	2
1243	Diabetes mellitus Typ 1 und Typ 2. , 2005, , 402-418.		0
1245	Hypertonie. , 2005, , 377-396.		0
1246	Arterielle Hypertonie bei Diabetes mellitus. , 2005, , 26-39.		0
1247	Stoffwechsel des Herzens bei Diabetes. , 2005, , 101-121.		0
1248	Diuretics and β -Adrenergic Blockers in the Management of Hypertension in the Elderly. , 2005, , 297-319.		0
1249	Supporting Evidence-Based Endocrine Practice. , 2006, , 87-100.		0
1250	Introduction to Diabetes. , 2006, , 1-37.		2
1251	Epidemiology and Prevention of Cardiovascular Disease in Diabetes. , 2009, , 19-33.		0
1253	Beta-Blocker Controversies. , 2007, , 37-42.		0
1255	Hypertension Controversies. , 2007, , 137-157.		0
1256	Diabetes mellitus Typ 1 und Typ 2. , 2007, , 448-465.		0
1257	Artist [®] Tablets (Carvedilol) for Hypertensive Patients in Japan. Drugs in R and D, 2011, 11, 191-205.	2.2	0
1259	Supporting People With Type 2 Diabetes in the Effective Use of Their Medicine Through Mobile Health Technology Integrated With Clinical Care to Reduce Cardiovascular Risk: Protocol for an Effectiveness and Cost-effectiveness Randomized Controlled Trial. JMIR Research Protocols, 2022, 11, e32918.	1.0	1
1260	Cardiovascular therapeutics: A new potential for anxiety treatment?. Medicinal Research Reviews, 2022, 42, 1202-1245.	10.5	10
1261	Hypertension and Diabetes. , 2022, , 263-291.		2

#	ARTICLE	IF	CITATIONS
1262	Vascular Function and Diabetes Mellitus. , 0 , 232-244.		2
1263	Epidemiology and Genetics of Diabetic Retinopathy. , 2022 , 2935-2953.		0
1264	Î²-blocking agents. , 2013 , 1-37.		2
1266	<scp>EndoBarrier</scp> treatment for longstanding type 2 diabetes and obesity: outcomes one year after <scp>EndoBarrier</scp> in 90 consecutively treated patients. Practical Diabetes, 2022, 39, 13.	0.3	1
1267	Cardiometabolism: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks. Canadian Journal of Physiology and Pharmacology, 0 , .	1.4	0
1269	Trends in glycemic control, cardiovascular risk factors and chronic complications of type 2 diabetes, 2012â€“2016, in a healthcare area of Barcelona. Diabetes Research and Clinical Practice, 2022, 190, 110014.	2.8	2
1270	Glycemia Reduction in Type 2 Diabetes â€” Microvascular and Cardiovascular Outcomes. New England Journal of Medicine, 2022, 387, 1075-1088.	27.0	62
1271	Self-Assessment of Outpatient Management of Hypertension in Diabetics. European Journal of Medical and Health Sciences, 2022, 4, 66-69.	0.2	0
1272	Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes. Biochemical Pharmacology, 2022, 206, 115304.	4.4	5
1273	Editorâ€™s Pick: Addressing Hypertension in the Patient with Type 2 Diabetes Mellitus: Pathogenesis, Goals, and Therapeutic Approach. European Medical Journal Diabetes, 0 , 84-92.	4.0	1
1274	Blood Pressure-Lowering Treatment and Macrovascular Events. Updates in Hypertension and Cardiovascular Protection, 2023 , 305-326.	0.1	0
1275	Choice of Antihypertensive Drugs and Antihypertensive Drug Combination in Diabetes. Updates in Hypertension and Cardiovascular Protection, 2023 , 389-403.	0.1	0
1276	Renal Hypertension: Etiology and Management. , 2023 , 1337-1362.		0
1277	Blood pressure control for diabetic retinopathy. The Cochrane Library, 2023, 2023, .	2.8	6
1279	Type 2 diabetes management: from a glucose-centric approach to cardio-renal risk reduction. , 2023 , 221-232.		0
1281	Hypertension: setting the treatment targets â€” a consensus emerges. International Journal of Clinical Practice, 1999, 53, 87-88.	1.7	1
1282	CONSIDERATIONS FOR DRUG THERAPY IN HYPERTENSION. International Journal of Clinical Practice, 2001, 55, 32-40.	1.7	0
1283	Renin-Angiotensin-Aldosterone System in Diabetic Cardiovascular Complications. Contemporary Cardiology, 2023 , 863-894.	0.1	0

#	ARTICLE	IF	CITATIONS
1284	Association of lactate dehydrogenase and diabetic retinopathy in <sc>US</sc> adults with diabetes mellitus. Journal of Diabetes, 0, , .	1.8	1
1287	Modern ideas about the consequences of sympathoadrenal hyperactivation in hypertensive patients with metabolic disorders: modulation possibilities. Russian Journal of Cardiology, 2023, 28, 5681.	1.4	0
1290	Risk Factors of Chronic Kidney Disease Progression: Between Old and New Concepts. Journal of Clinical Medicine, 2024, 13, 678.	2.4	0
1291	Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMIT-D pilot): results of a feasibility randomised trial. Pilot and Feasibility Studies, 2024, 10, .	1.2	0
1293	Beta-blockers and chronic kidney disease: a literature review. Kachestvennaya Klinicheskaya Praktika, 2024, , 68-77.	0.5	0